<article article-type="article" specific-use="production" xml:lang="en" xmlns:hw="org.highwire.hpp" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:ref="http://schema.highwire.org/Reference" xmlns:hwp="http://schema.highwire.org/Journal" xmlns:l="http://schema.highwire.org/Linking" xmlns:r="http://schema.highwire.org/Revision" xmlns:x="http://www.w3.org/1999/xhtml" xmlns:app="http://www.w3.org/2007/app" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:nlm="http://schema.highwire.org/NLM/Journal" xmlns:a="http://www.w3.org/2005/Atom" xmlns:c="http://schema.highwire.org/Compound" xmlns:hpp="http://schema.highwire.org/Publishing"><front><journal-meta><journal-id journal-id-type="hwp">biorxiv</journal-id><journal-id journal-id-type="publisher-id">BIORXIV</journal-id><journal-title>bioRxiv</journal-title><abbrev-journal-title abbrev-type="publisher">bioRxiv</abbrev-journal-title><publisher><publisher-name>Cold Spring Harbor Laboratory</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.1101/298836</article-id><article-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;298836v1</article-id><article-id pub-id-type="other" hwp:sub-type="pisa-master">biorxiv;298836</article-id><article-id pub-id-type="other" hwp:sub-type="slug">298836</article-id><article-id pub-id-type="other" hwp:sub-type="tag">298836</article-id><article-version>1.1</article-version><article-categories><subj-group subj-group-type="author-type"><subject>Regular Article</subject></subj-group><subj-group subj-group-type="heading"><subject>New Results</subject></subj-group><subj-group subj-group-type="hwp-journal-coll" hwp:journal-coll-id="Systems Biology" hwp:journal="biorxiv"><subject>Systems Biology</subject></subj-group></article-categories><title-group><article-title hwp:id="article-title-1">Estimation of the cancer risk induced by rejuvenation therapy with young blood and treatment recommendations</article-title></title-group><author-notes hwp:id="author-notes-1"><corresp id="cor1" hwp:id="corresp-1">Correspondence: <email hwp:id="email-1">mmh@theoretical-biology.de</email></corresp></author-notes><contrib-group hwp:id="contrib-group-1"><contrib contrib-type="author" corresp="yes" hwp:id="contrib-1"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-4300-2474</contrib-id><name name-style="western" hwp:sortable="Meyer-Hermann Michael"><surname>Meyer-Hermann</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-1" hwp:rel-id="aff-1">1</xref><xref ref-type="aff" rid="a2" hwp:id="xref-aff-2-1" hwp:rel-id="aff-2">2</xref><xref ref-type="aff" rid="a3" hwp:id="xref-aff-3-1" hwp:rel-id="aff-3">3</xref><object-id pub-id-type="other" hwp:sub-type="orcid" xlink:href="http://orcid.org/0000-0002-4300-2474"/></contrib><aff id="a1" hwp:id="aff-1" hwp:rev-id="xref-aff-1-1"><label>1</label><institution hwp:id="institution-1">Department of Systems Immunology and Braunschweig Integrated Centre of Systems Biology, Helmholtz Centre for Infection Research</institution>, Rebenring 56, 38106 Braunschweig, <country>Germany</country></aff><aff id="a2" hwp:id="aff-2" hwp:rev-id="xref-aff-2-1"><label>2</label><institution hwp:id="institution-2">Centre for Individualised Infection Medicine (CIIM)</institution>, Hannover, <country>Germany</country></aff><aff id="a3" hwp:id="aff-3" hwp:rev-id="xref-aff-3-1"><label>3</label><institution hwp:id="institution-3">Institute for Biochemistry, Biotechnology and Bioinformatics, Technische Universität Braun-schweig</institution>, Braunschweig, <country>Germany</country></aff></contrib-group><pub-date pub-type="epub-original" hwp:start="2018"><year>2018</year></pub-date><pub-date pub-type="hwp-created" hwp:start="2018-04-11T03:03:22-07:00">
    <day>11</day><month>4</month><year>2018</year>
  </pub-date><pub-date pub-type="hwp-received" hwp:start="2018-04-11T03:03:22-07:00">
    <day>11</day><month>4</month><year>2018</year>
  </pub-date><pub-date pub-type="epub" hwp:start="2018-04-11T03:10:09-07:00">
    <day>11</day><month>4</month><year>2018</year>
  </pub-date><pub-date pub-type="epub-version" hwp:start="2018-04-11T03:10:09-07:00">
    <day>11</day><month>4</month><year>2018</year>
  </pub-date><elocation-id>298836</elocation-id><history hwp:id="history-1">
<date date-type="received" hwp:start="2018-04-10"><day>10</day><month>4</month><year>2018</year></date>
<date date-type="rev-recd" hwp:start="2018-04-10"><day>10</day><month>4</month><year>2018</year></date>
<date date-type="accepted" hwp:start="2018-04-11"><day>11</day><month>4</month><year>2018</year></date>
</history><permissions><copyright-statement hwp:id="copyright-statement-1">© 2018, Posted by Cold Spring Harbor Laboratory</copyright-statement><copyright-year>2018</copyright-year><license hwp:id="license-1"><p hwp:id="p-1">The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission.</p></license></permissions><self-uri xlink:href="298836.pdf" content-type="pdf" xlink:role="full-text"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/abstract" xlink:role="abstract" content-type="xhtml+xml" hwp:variant="yes"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/full-text" xlink:href="file:/content/biorxiv/vol0/issue2019/pdf/298836v1.pdf" hwp:variant="yes" content-type="pdf" xlink:role="full-text"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/full-text" xlink:role="full-text" content-type="xhtml+xml" hwp:variant="yes"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/source" xlink:role="source" content-type="xml" xlink:show="none" hwp:variant="yes"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/original" xlink:role="original" content-type="xml" xlink:show="none" hwp:variant="yes" xlink:href="298836.xml"/><self-uri content-type="abstract" xlink:href="file:/content/biorxiv/vol0/issue2019/abstracts/298836v1/298836v1.htslp"/><self-uri content-type="fulltext" xlink:href="file:/content/biorxiv/vol0/issue2019/fulltext/298836v1/298836v1.htslp"/><abstract hwp:id="abstract-1"><title hwp:id="title-1">Abstract</title><p hwp:id="p-2">In recent years the transfer of blood from young to old individuals was shown to bear the potential of rejuvenation of stem cell activity. While this process might increase life expectancy by prolonging functionality of organs, higher cell replication rates bear also the risk of cancer. The extent of this risk is not known.</p><p hwp:id="p-3">While it is difficult to evaluate this cancer risk in experiments, this is possible with a mathematical model for tissue homeostasis by stem cell replication and associated cancer risk. The model suggests that young blood treatments can induce a substantial delay of organ failure with only minor increase in cancer risk. The benefit of rejuvenation therapy as well as the impact on cancer risk depend on the biological age at the time of treatment and on the overall cell turnover rate of the organs. Different organs have to be considered separately in the planning of the systemic treatment. In particular, the model predicts that the treatment schedules successfully applied in mice are not directly transferable to humans and guidelines for successful protocols are proposed. The model presented here may be used as a guidance for the development of treatment protocols.</p><sec hwp:id="sec-1"><title hwp:id="title-2">Additional information</title><p hwp:id="p-4">There is NO competing interests.</p></sec></abstract><counts><page-count count="27"/></counts></article-meta></front><body><p hwp:id="p-5">Biological organisms like humans accumulate DNA damage in replicating cells inducing many processes summarised under the general term of ageing. Without DNA damage, stem cell activity could be maintained on a level that guarantees better homeostasis of the organism. However, stem-cell function declines over time and is associated with ageing [<xref ref-type="bibr" rid="c1" hwp:id="xref-ref-1-1" hwp:rel-id="ref-1">1</xref>]. There is increasing evidence that the process of decline of stem-cell function can be reverted by transfer of blood from younger individuals in liver [<xref ref-type="bibr" rid="c2" hwp:id="xref-ref-2-1" hwp:rel-id="ref-2">2</xref>] and brain [<xref ref-type="bibr" rid="c3" hwp:id="xref-ref-3-1" hwp:rel-id="ref-3">3</xref>]. This was shown with heterochronic parabiosis mouse models [<xref ref-type="bibr" rid="c4" hwp:id="xref-ref-4-1" hwp:rel-id="ref-4">4</xref>, <xref ref-type="bibr" rid="c5" hwp:id="xref-ref-5-1" hwp:rel-id="ref-5">5</xref>], in which young and old mice share their circulatory system.</p><p hwp:id="p-6">It is becoming increasingly clear that it is not the cellular components of the young blood but soluble factors that mediate the positive effect on stem-cells in various organs including brain, liver, and muscles [<xref ref-type="bibr" rid="c6" hwp:id="xref-ref-6-1" hwp:rel-id="ref-6">6</xref>]. The determination of those systemic factors responsible for reactivation of stem-cells is ongoing [<xref ref-type="bibr" rid="c7" hwp:id="xref-ref-7-1" hwp:rel-id="ref-7">7</xref>]. More recent data suggest that it is not a property of young blood, but the dilution of inhibitory factors in old blood that would be responsible for the effect [<xref ref-type="bibr" rid="c8" hwp:id="xref-ref-8-1" hwp:rel-id="ref-8">8</xref>].</p><p hwp:id="p-7">Irrespective of the actual mechanism that induced improved tissue homeostasis, reactivation of damaged and silenced stem cells might well induce a higher risk of developing age-related diseases like cancer [<xref ref-type="bibr" rid="c9" hwp:id="xref-ref-9-1" hwp:rel-id="ref-9">9</xref>]. While it is impossible to quantify the degree to which stem cell re-activation would increase the risk of cancer in experimental settings, this is possible based on theoretical methods and is the main objective of the present research. With a minimum of assumptions the presented analysis predicts the price of a stem cell rejuvenation therapy in terms of the impact of the therapy on cancer risk.</p><sec id="s1" hwp:id="sec-2"><title hwp:id="title-3">Results</title><sec id="s1a" hwp:id="sec-3"><title hwp:id="title-4">A simple and generic model of organ homeostasis and cancer development</title><p hwp:id="p-8">In order to ensure predictive power of the mathematical model it has to be constructed on the basis of rather generic assumptions. The model complexity is chosen such that the driving question, whether cancer risk is under control during rejuvenation therapy or not, can be addressed, avoiding any speculation on molecular mechanisms. The model (see Methods: <italic toggle="yes">Model equations and analytical solution</italic>) distinguishes stem (<italic toggle="yes">S</italic>) and tissue cells (<italic toggle="yes">T</italic>). It further distinguishes two reasons for death: organ failure and cancer. More specifically the model is based on the following set of assumptions:
<list list-type="bullet" hwp:id="list-1"><list-item hwp:id="list-item-1"><p hwp:id="p-9">Tissue cells (<italic toggle="yes">T</italic>) have a natural life time (death rate <italic toggle="yes">δ</italic>) and are replenished by stem cell (<italic toggle="yes">S</italic>) division (proliferation rate <italic toggle="yes">p</italic>).</p></list-item><list-item hwp:id="list-item-2"><p hwp:id="p-10">The ratio of stem to tissue cells is 1:1000.</p></list-item><list-item hwp:id="list-item-3"><p hwp:id="p-11">Humans have a life time (Θ) of 80 years, mice of 2 years.</p></list-item><list-item hwp:id="list-item-4"><p hwp:id="p-12">Death is induced by organ failure, which happens when the total number of tissue cells hits a fraction (<italic toggle="yes">f</italic>) of 50%.</p></list-item><list-item hwp:id="list-item-5"><p hwp:id="p-13">Both, tissue and stem cells accumulate damage (mutation rate <italic toggle="yes">γ</italic>). The kind of damage is not distinguished and only the number of accumulated damage events is considered.</p></list-item><list-item hwp:id="list-item-6"><p hwp:id="p-14">Damaged stem cells pass their damage state to tissue progeny in the course of homeostatic division.</p></list-item><list-item hwp:id="list-item-7"><p hwp:id="p-15">The damage rate (<italic toggle="yes">γ</italic>) is constant.</p></list-item><list-item hwp:id="list-item-8"><p hwp:id="p-16">Cancer is induced at a critical number of mutations per cell (<italic toggle="yes">c</italic>).</p></list-item><list-item hwp:id="list-item-9"><p hwp:id="p-17">Cancer risk at the age of 80 is <italic toggle="yes">ξ</italic> = 30%.</p></list-item></list></p><p hwp:id="p-18">The rate of point mutations in human adult stem cells was measured in the range of 40 mutations per year [<xref ref-type="bibr" rid="c10" hwp:id="xref-ref-10-1" hwp:rel-id="ref-10">10</xref>], where an approximately linear relationship of the number of mutations over age was found. This supports the assumed constant damage rate (<italic toggle="yes">γ</italic>). While the number of stem cell mutations correlates with cancer incidence [<xref ref-type="bibr" rid="c11" hwp:id="xref-ref-11-1" hwp:rel-id="ref-11">11</xref>], this absolute frequency of mutations is still difficult to be related to cancer risk because not all of these mutations happen in oncogenic regions of the genome. Furthermore, the immune system is removing pathogenic cells, which makes the absolute number of mutations associated with cancer unclear. In order to keep the model simple, I relied on the linear accumulation of mutations over age and fixed the cancer-inducing number of mutations to <italic toggle="yes">c</italic> = 10 per cell. This choice can be considered as a worst case scenario for the cancer risk induced by rejuvenation therapy because, on the one hand, cancer is expected to be induced by more than 10 accumulated mutations, and, on the other hand, with <italic toggle="yes">c &gt;</italic> 10 the induced cancer risk is getting smaller in the model, as was revealed by a robustness analysis (see Methods: <italic toggle="yes">Robustness of the statements</italic>).</p><p hwp:id="p-19">As the division (<italic toggle="yes">p</italic>) and the cell damage rate (<italic toggle="yes">γ</italic>) are determined by the life expectancy (Θ; see Methods: <italic toggle="yes">Determination of the division rate</italic>) and the cancer risk (<italic toggle="yes">ξ</italic>; see Methods: <italic toggle="yes">Determination of the mutation rate</italic>) at this age, respectively, this model has only a single free parameter: The cell death rate <italic toggle="yes">δ</italic>, which controls the overall turnover rate of tissue cells. The turnover rate is a tissue specific property and different values are considered in the following. Parameter sets for <italic toggle="yes">low, intermediate</italic>, and <italic toggle="yes">high turnover</italic> are defined in <xref rid="tbl1" ref-type="table" hwp:id="xref-table-wrap-1-1" hwp:rel-id="T1">Table 1</xref> and used as reference parameter sets.</p><table-wrap id="tbl1" orientation="portrait" position="float" hwp:id="T1" hwp:rev-id="xref-table-wrap-1-1 xref-table-wrap-1-2 xref-table-wrap-1-3 xref-table-wrap-1-4 xref-table-wrap-1-5 xref-table-wrap-1-6 xref-table-wrap-1-7 xref-table-wrap-1-8 xref-table-wrap-1-9 xref-table-wrap-1-10 xref-table-wrap-1-11 xref-table-wrap-1-12 xref-table-wrap-1-13 xref-table-wrap-1-14 xref-table-wrap-1-15 xref-table-wrap-1-16 xref-table-wrap-1-17"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;298836v1/TBL1</object-id><object-id pub-id-type="other" hwp:sub-type="slug">T1</object-id><object-id pub-id-type="publisher-id">tbl1</object-id><label>Table 1:</label><caption hwp:id="caption-1"><title hwp:id="title-5">Reference model parameter sets.</title><p hwp:id="p-20">The rates <italic toggle="yes">p</italic>, <italic toggle="yes">p</italic><sub>max</sub>, <italic toggle="yes">δ</italic>, and <italic toggle="yes">γ</italic> are given per year. Life expectancy Θ and half time <italic toggle="yes">K</italic> are in years. Note that <italic toggle="yes">p</italic> (Methods: <italic toggle="yes">Determination of the division rate</italic>), <italic toggle="yes">p</italic><sub>max</sub> (Methods: <italic toggle="yes">Determination of the division rate of perfect homeostasis</italic>), and <italic toggle="yes">γ</italic> (Methods: <italic toggle="yes">Determination of the mutation rate</italic>) are calculated from side conditions, thus, are not free parameters. The turnover rate is controlled by the cell death rate <italic toggle="yes">δ</italic>, where <italic toggle="yes">low</italic>, <italic toggle="yes">intermediate</italic>, and <italic toggle="yes">high</italic> turnover is used for simulations of humans. In runs with age-dependent <italic toggle="yes">p</italic>(<italic toggle="yes">t</italic>), the value for <italic toggle="yes">p</italic> is replaced by the three values <italic toggle="yes">p</italic><sub>max</sub>, <italic toggle="yes">K</italic>, and <italic toggle="yes">n</italic> (see <xref ref-type="disp-formula" rid="eqn15" hwp:id="xref-disp-formula-15-1" hwp:rel-id="disp-formula-15">Eq. (15)</xref>), where <italic toggle="yes">p</italic><sub><italic toggle="yes">max</italic></sub> and <italic toggle="yes">K</italic> are calculated from side conditions (see Methods: <italic toggle="yes">Age-dependent stem cell division rate</italic>). Deviations from these sets are explicitly mentioned in the text. The robustness of the results against parameter variation is discussed in Methods: <italic toggle="yes">Robustness of the statements</italic>.</p></caption><graphic xlink:href="298836_tbl1" position="float" orientation="portrait" hwp:id="graphic-1"/></table-wrap><p hwp:id="p-21">Starting from a young individual without any damaged cell, the time course of cell damages over age is depicted in <xref rid="fig1" ref-type="fig" hwp:id="xref-fig-1-1" hwp:rel-id="F1">Figure 1</xref>. In this setting, the age of death is determined by the time, at which the total number of cells building up the virtual organ hits the fraction <italic toggle="yes">f</italic> = 50%. This time will be denoted as <italic toggle="yes">age of organ failure</italic> in the following. The age of cancer onset is determined by the time when the sum of all cells with <italic toggle="yes">c</italic> = 10 or more mutations passes the limit of 1 cell (purple lines in <xref rid="fig1" ref-type="fig" hwp:id="xref-fig-1-2" hwp:rel-id="F1">Figure 1</xref>). Assuming ergodicity, one can state that a number of cells with 10 or more mutations below 1 reflects the cancer risk at a particular age. In the following, the <italic toggle="yes">age of cancer risk ξ</italic> will be discussed, which denotes the age at which the number of cells with <italic toggle="yes">c</italic> = 10 or more mutations reaches <italic toggle="yes">ξ</italic> = 0.3.</p><fig id="fig1" position="float" fig-type="figure" orientation="portrait" hwp:id="F1" hwp:rev-id="xref-fig-1-1 xref-fig-1-2"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;298836v1/FIG1</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F1</object-id><object-id pub-id-type="publisher-id">fig1</object-id><label>Figure 1:</label><caption hwp:id="caption-2"><title hwp:id="title-6">Damage dynamics in stem and tissue cells.</title><p hwp:id="p-22">Only undamaged stem (<bold>A</bold>) and tissue cells (<bold>B</bold>) exist in the beginning (initial conditions are <italic toggle="yes">σ</italic><sub><italic toggle="yes">i</italic></sub> = <italic toggle="yes">τ</italic><sub><italic toggle="yes">i</italic></sub> = 0 for <italic toggle="yes">i &gt;</italic> 0 in <xref ref-type="disp-formula" rid="eqn2" hwp:id="xref-disp-formula-2-1" hwp:rel-id="disp-formula-2">Eq. (2)</xref>). Parameters of <italic toggle="yes">low turnover</italic> in <xref rid="tbl1" ref-type="table" hwp:id="xref-table-wrap-1-2" hwp:rel-id="T1">Table 1</xref> were used. The number of cells with different numbers of mutations over the life time is shown with different colours. The line with 10 mutations recollects all cells with <italic toggle="yes">c</italic> = 10 or more mutations.</p></caption><graphic xlink:href="298836_fig1" position="float" orientation="portrait" hwp:id="graphic-2"/></fig></sec><sec id="s1a1" hwp:id="sec-4"><title hwp:id="title-7">Rejuvenation therapy impacts on the age of organ failure</title><p hwp:id="p-23">Blood transfer from young individuals is meant to reactivate stem cell division. In the model this is reflected by changing the stem cell division rate <italic toggle="yes">p</italic>. <xref rid="fig2" ref-type="fig" hwp:id="xref-fig-2-1" hwp:rel-id="F2">Figure 2</xref> shows how the ages of organ failure <xref ref-type="disp-formula" rid="eqn14" hwp:id="xref-disp-formula-14-1" hwp:rel-id="disp-formula-14">Eq. (14)</xref> and cancer risk <italic toggle="yes">ξ</italic> <xref ref-type="disp-formula" rid="eqn12" hwp:id="xref-disp-formula-12-1" hwp:rel-id="disp-formula-12">Eq. (12)</xref> depend on the induced division rate, where the induced division rate is assumed constant over the life time. The untreated division rate determined in <xref ref-type="disp-formula" rid="eqn6" hwp:id="xref-disp-formula-6-1" hwp:rel-id="disp-formula-6">Eq. (6)</xref> (vertical dashed line), by construction, induces organ failure and a cancer risk of <italic toggle="yes">ξ</italic> = 0.3 at the age of Θ = 80 years. The division rate for perfect tissue homeostasis determined in <xref ref-type="disp-formula" rid="eqn11" hwp:id="xref-disp-formula-11-1" hwp:rel-id="disp-formula-11">Eq. (11)</xref> prohibits death by organ failure. Surprisingly, the result clearly shows that the age of organ failure is highly sensitive to the division rate (red line in <xref rid="fig2" ref-type="fig" hwp:id="xref-fig-2-2" hwp:rel-id="F2">Figure 2</xref>) while the age of cancer risk <italic toggle="yes">ξ</italic> is hardly changing (blue line in <xref rid="fig2" ref-type="fig" hwp:id="xref-fig-2-3" hwp:rel-id="F2">Figure 2</xref>). For a young blood therapy inducing stem cell replication to a degree that organ failure happens at the age of 400 (this is achieved by doubling the stem cell replication rate), the age at which the cancer risk reaches 30% is shifted from 80 to 78.</p><fig id="fig2" position="float" fig-type="figure" orientation="portrait" hwp:id="F2" hwp:rev-id="xref-fig-2-1 xref-fig-2-2 xref-fig-2-3 xref-fig-2-4 xref-fig-2-5"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;298836v1/FIG2</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F2</object-id><object-id pub-id-type="publisher-id">fig2</object-id><label>Figure 2:</label><caption hwp:id="caption-3"><title hwp:id="title-8">Ages of organ failure or cancer risk <italic toggle="yes">ξ</italic> in dependence on the cell renewal rate.</title><p hwp:id="p-24">The age of organ failure (red line, <xref ref-type="disp-formula" rid="eqn14" hwp:id="xref-disp-formula-14-2" hwp:rel-id="disp-formula-14">Eq. (14)</xref>) is highly sensitive to changes in the cell renewal rate (<italic toggle="yes">p</italic>) while the age of cancer risk <italic toggle="yes">ξ</italic> (blue line, <xref ref-type="disp-formula" rid="eqn12" hwp:id="xref-disp-formula-12-2" hwp:rel-id="disp-formula-12">Eq. (12)</xref>) remains comparably stable. Unmodified stem cell renewal <italic toggle="yes">p</italic><sub>normal</sub> (see <xref ref-type="disp-formula" rid="eqn6" hwp:id="xref-disp-formula-6-2" hwp:rel-id="disp-formula-6">Eq. (6)</xref>) and perfect cell renewal <italic toggle="yes">p</italic><sub>juvenile</sub> (see <xref ref-type="disp-formula" rid="eqn11" hwp:id="xref-disp-formula-11-2" hwp:rel-id="disp-formula-11">Eq. (11)</xref>) are marked by the vertical dashed and full lines, respectively. Between the red and the vertical black line, <xref ref-type="disp-formula" rid="eqn14" hwp:id="xref-disp-formula-14-3" hwp:rel-id="disp-formula-14">Eq. (14)</xref> has no solution, which means that organ failure never happens. Parameter set for low turnover in <xref rid="tbl1" ref-type="table" hwp:id="xref-table-wrap-1-3" hwp:rel-id="T1">Table 1</xref>.</p></caption><graphic xlink:href="298836_fig2" position="float" orientation="portrait" hwp:id="graphic-3"/></fig></sec><sec id="s1b" hwp:id="sec-5"><title hwp:id="title-9">Organ failure is delayed with limited cancer risk</title><p hwp:id="p-25">A life long treatment with young blood is not a realistic scenario. Assuming a treatment limited to a duration of 10 years starting at different ages (see Methods: <italic toggle="yes">Treatment at particular ages</italic>), a similar picture in terms of sensitivity of the ages of organ failure and cancer risk emerges (full lines in <xref rid="fig3" ref-type="fig" hwp:id="xref-fig-3-1" hwp:rel-id="F3">Figure 3</xref>). The overall effect on the age of organ failures is smaller than for life long treatments (<xref rid="fig3" ref-type="fig" hwp:id="xref-fig-3-2" hwp:rel-id="F3">Figure 3A,B</xref>). With an induced division rate of perfect tissue homeostasis <xref ref-type="disp-formula" rid="eqn11" hwp:id="xref-disp-formula-11-3" hwp:rel-id="disp-formula-11">Eq. (11)</xref>, organ failure happens at ages between 85 and 100 years, and the cancer risk of <italic toggle="yes">ξ</italic> = 30% is reached at ages around 79 ± 1 years. When the same treatment is repeated three times every 10 years with pausing intervals of 10 years (dotted lines, <xref rid="fig3" ref-type="fig" hwp:id="xref-fig-3-3" hwp:rel-id="F3">Figure 3</xref>), organ failure happens at ages between 110 and 150 years and the cancer risk of 30% is reached at the age of 78 ± 1 years. While the absolute numbers have to be interpreted carefully, the difference in the sensitivity of both read-outs is a stable finding.</p><fig id="fig3" position="float" fig-type="figure" orientation="portrait" hwp:id="F3" hwp:rev-id="xref-fig-3-1 xref-fig-3-2 xref-fig-3-3 xref-fig-3-4 xref-fig-3-5 xref-fig-3-6 xref-fig-3-7 xref-fig-3-8 xref-fig-3-9 xref-fig-3-10 xref-fig-3-11 xref-fig-3-12 xref-fig-3-13 xref-fig-3-14 xref-fig-3-15"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;298836v1/FIG3</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F3</object-id><object-id pub-id-type="publisher-id">fig3</object-id><label>Figure 3:</label><caption hwp:id="caption-4"><title hwp:id="title-10">Organ failure and cancer risk with time-limited rejuvenation treatment.</title><p hwp:id="p-26">The analytical solution <xref ref-type="disp-formula" rid="eqn2" hwp:id="xref-disp-formula-2-2" hwp:rel-id="disp-formula-2">Eq. (2)</xref> together with 10 year treatments (Methods: <italic toggle="yes">Treatment at particular ages</italic>) is analysed for ages of organ failure (<bold>A,C</bold>) and cancer risk <italic toggle="yes">ξ</italic> (<bold>B,D</bold>) in dependence on the age of first treatment (colors) and with different induced renewal rate <italic toggle="yes">p</italic> (horizontal axes). A single treatment (full lines, circles) is compared to three treatments with interruptions of 10 years (dashed lines, crosses). Vertical lines denote the renewal rate of humans with a life expectancy of 80 years (dashed black line) and with perfect tissue homeostasis (full black line). Parameter set of low (<bold>A,B</bold>) and high (<bold>C,D</bold>) turnover in <xref rid="tbl1" ref-type="table" hwp:id="xref-table-wrap-1-4" hwp:rel-id="T1">Table 1</xref>. Compare <xref ref-type="fig" rid="figS1" hwp:id="xref-fig-7-1" hwp:rel-id="F7">Supplementary Figure 1</xref> for intermediate turnover rates.</p></caption><graphic xlink:href="298836_fig3" position="float" orientation="portrait" hwp:id="graphic-4"/></fig><p hwp:id="p-27">Organ failure is delayed the more the later the treatment is started. Cancer risk is increased correspondingly. Surprisingly, when the first of the three treatment is started at an age of 42 or later, cancer risk is getting lower when the treatment is started later (see <xref rid="fig3" ref-type="fig" hwp:id="xref-fig-3-4" hwp:rel-id="F3">Figure 3A,B</xref>; blue and shorter wavelength curves). In this regime, rejuvenation treatment has a strong effect on the delay of organ failure with a comparably small increased risk of cancer. However, overall organ functionality is lower when treatment is started later. The treated individual faces a physiological state that is kept above but near of the organ failure threshold, which implies a lower life quality compared to treatments started at younger age.</p></sec><sec id="s1c" hwp:id="sec-6"><title hwp:id="title-11">High-turnover organs are more sensitive to rejuvenation treatment but less stable</title><p hwp:id="p-28">The investigation was built on organs with a low turnover rate (see <xref rid="tbl1" ref-type="table" hwp:id="xref-table-wrap-1-5" hwp:rel-id="T1">Table 1</xref>, <italic toggle="yes">low</italic>). For high turnover organs (<xref rid="fig3" ref-type="fig" hwp:id="xref-fig-3-5" hwp:rel-id="F3">Figure 3C,D</xref>), the sensitivity of the age of organ failure to a single rejuvenation treatment is even higher. With an induced division rate of perfect tissue homeostasis <xref ref-type="disp-formula" rid="eqn11" hwp:id="xref-disp-formula-11-4" hwp:rel-id="disp-formula-11">Eq. (11)</xref>, organ failure happens at ages between 90 and 160 years, while the age of cancer risk <italic toggle="yes">ξ</italic> is kept between 76 and 80 years. With three treatments of 10 years, the age of organ failure can be delayed to ages of 130 to 200 years, while the cancer risk is not further increased. Importantly, for high turnover organs, a single rejuvenation treatment can delay the age of organ failure to 120 years, while inducing no major change in the cancer risk (<xref rid="fig3" ref-type="fig" hwp:id="xref-fig-3-6" hwp:rel-id="F3">Figure 3C,D</xref>; full green and longer wavelength lines).</p><p hwp:id="p-29">Failure of high turnover organs cannot be further delayed by higher than perfect homeostasis <italic toggle="yes">p</italic><sub>juvenile</sub> stem cell replication rates. However, cancer risk enters a non-linear regime at higher replication rates (<xref rid="fig3" ref-type="fig" hwp:id="xref-fig-3-7" hwp:rel-id="F3">Figure 3D</xref>). Organs with higher turnover rates react with higher or lower cancer risks than for low turnover organs depending on how and when the treatment is applied. There is hardly any increased cancer risk when the treatment is done at young age, irrespective of the target replication rate of the treatment. There is a transition to a strong impact on cancer risk at the age of 35 to 42. Cancer risk is highest for treatments started at the age of 56 and decreases again at higher ages (<xref rid="fig4" ref-type="fig" hwp:id="xref-fig-4-1" hwp:rel-id="F4">Figure 4</xref>). As the treatment is applied systemically, it will always also affect high turnover organs. The presented results illustrate that the timing and the dosage have to be planned quantitatively in order to avoid adverse effects.</p><fig id="fig4" position="float" fig-type="figure" orientation="portrait" hwp:id="F4" hwp:rev-id="xref-fig-4-1"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;298836v1/FIG4</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F4</object-id><object-id pub-id-type="publisher-id">fig4</object-id><label>Figure 4:</label><caption hwp:id="caption-5"><title hwp:id="title-12">Optimal treatment age to minimise cancer risk in high turnover organs.</title><p hwp:id="p-30">Same data as in <xref rid="fig3" ref-type="fig" hwp:id="xref-fig-3-8" hwp:rel-id="F3">Figure 3C,D</xref> with a single 10 year treatment. The age of cancer risk <italic toggle="yes">ξ</italic> is shown in dependence on the time of treatment (horizontal axis) for different strength of treatment reflected by the p-factor (colors). Parameters of high turnover in <xref rid="tbl1" ref-type="table" hwp:id="xref-table-wrap-1-6" hwp:rel-id="T1">Table 1</xref>.</p></caption><graphic xlink:href="298836_fig4" position="float" orientation="portrait" hwp:id="graphic-5"/></fig></sec><sec id="s1d" hwp:id="sec-7"><title hwp:id="title-13">Limited cancer risk also in a model with age-dependent loss of stem-cell replication</title><p hwp:id="p-31">A general tendency of rejuvenation treatment is that the later the treatment is started, the more organ failure is delayed and the more cancer risk is increased (<xref rid="fig3" ref-type="fig" hwp:id="xref-fig-3-9" hwp:rel-id="F3">Figure 3</xref>). However, this result might rely on the assumption that stem cell replication is constant over the life time but for the periods of treatment. While this assumption is a good approximation for skin tissue, in which stem cell replication is widely conserved at all ages [<xref ref-type="bibr" rid="c12" hwp:id="xref-ref-12-1" hwp:rel-id="ref-12">12</xref>], other organs exhibit a decrease of the stem cell replication rate with age [<xref ref-type="bibr" rid="c1" hwp:id="xref-ref-1-2" hwp:rel-id="ref-1">1</xref>]. For example, hematopoietic stem cells lose power in the course of ageing [<xref ref-type="bibr" rid="c13" hwp:id="xref-ref-13-1" hwp:rel-id="ref-13">13</xref>, <xref ref-type="bibr" rid="c14" hwp:id="xref-ref-14-1" hwp:rel-id="ref-14">14</xref>]. The degree of this reduction is again organ specific. Assuming a Hill-function for the dependence of <italic toggle="yes">p</italic> on age (see Methods: <italic toggle="yes">Age-dependent stem cell division rate</italic>), the set of differential <xref ref-type="disp-formula" rid="eqn1" hwp:id="xref-disp-formula-1-1" hwp:rel-id="disp-formula-1">equations Eq. (1)</xref> cannot be solved analytically anymore and is solved numerically.</p><p hwp:id="p-32">Induction of higher stem cell replication rates in low turnover organs exhibits a qualitatively similar result as with constant <italic toggle="yes">p</italic> (<xref rid="fig5" ref-type="fig" hwp:id="xref-fig-5-1" hwp:rel-id="F5">Figure 5A,B</xref>). The initial (at birth) replication rates required for organ failure at ages above 100 are higher because of the loss of replication with increasing age. An increase of the replication rate to an absolute level has a stronger effect, the later in life the treatment is done. The sensitivity to the treatment of the age of organ failure is still substantially higher than the sensitivity of the age of cancer risk <italic toggle="yes">ξ</italic>.</p><fig id="fig5" position="float" fig-type="figure" orientation="portrait" hwp:id="F5" hwp:rev-id="xref-fig-5-1 xref-fig-5-2 xref-fig-5-3 xref-fig-5-4 xref-fig-5-5 xref-fig-5-6 xref-fig-5-7 xref-fig-5-8 xref-fig-5-9 xref-fig-5-10"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;298836v1/FIG5</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F5</object-id><object-id pub-id-type="publisher-id">fig5</object-id><label>Figure 5:</label><caption hwp:id="caption-6"><title hwp:id="title-14">Absolute versus relative impact of rejuvenation treatment in a model with age-dependent loss of stem-cell replication.</title><p hwp:id="p-33">The numerical solution of <xref ref-type="disp-formula" rid="eqn1" hwp:id="xref-disp-formula-1-2" hwp:rel-id="disp-formula-1">Eq. (1)</xref> together with 10 year treatments (Methods: <italic toggle="yes">Treatment at particular ages</italic>) is analysed for ages of organ failure (<bold>A,C</bold>) and cancer risk <italic toggle="yes">ξ</italic> (<bold>B,D</bold>) in dependence on the age of first treatment (colors) and on the strength of treatment (horizontal axes). Absolute (<bold>A,B</bold>) or relative improvements (<bold>C,D</bold>) of the renewal rate are distinguished. A single treatment (full lines, circles) is compared to three treatments with interruptions of 10 years (dashed lines, crosses). Vertical lines denote the renewal rate <italic toggle="yes">p</italic><sub><italic toggle="yes">juvenile</italic></sub> inducing perfect tissue homeostasis (full black line). Parameter of low turnover in <xref rid="tbl1" ref-type="table" hwp:id="xref-table-wrap-1-7" hwp:rel-id="T1">Table 1</xref> with age-dependent stem-cell replication rate <italic toggle="yes">p</italic> in <xref ref-type="disp-formula" rid="eqn15" hwp:id="xref-disp-formula-15-2" hwp:rel-id="disp-formula-15">Eq. (15)</xref>. For higher turnover rates compare <xref ref-type="fig" rid="figS2" hwp:id="xref-fig-8-1" hwp:rel-id="F8">Supplementary Figure 2</xref> (absolute renewal rates) and <xref ref-type="fig" rid="figS3" hwp:id="xref-fig-9-1" hwp:rel-id="F9">Supplementary Figure 3</xref> (relative renewal rates).</p></caption><graphic xlink:href="298836_fig5" position="float" orientation="portrait" hwp:id="graphic-6"/></fig></sec><sec id="s1e" hwp:id="sec-8"><title hwp:id="title-15">The mechanism of rejuvenation therapy impacts on the hierarchy of best treatment age</title><p hwp:id="p-34">Rejuvenation treatment with young blood at a particular age can either relatively improve the remaining stem cell replication activity or induce an absolute replication level. The mechanism of how young blood transfer improves stem cell replication is not known. Therefore, the aforementioned results, which were based on absolute renewal rates, are compared to results from a model with relative improvements of the renewal rate.</p><p hwp:id="p-35">When treatment with young blood induces an improved replication relative to the level of stem cell replication at the time of treatment, the situation changes in organs with low turnover rates (<xref rid="fig5" ref-type="fig" hwp:id="xref-fig-5-2" hwp:rel-id="F5">Figure 5C,D</xref>). At first, the overall impact on the ages of organ failure and cancer risk <italic toggle="yes">ξ</italic> is smaller. Secondly, the advantageous age of treatment is different: With a factor of 10 higher stem cell replication in young age, a substantial retardation of organ failure can be induced. However, the later the treatment is done, the weaker the effect, thus, inverting the result found with either constant stem cell replication (<xref rid="fig3" ref-type="fig" hwp:id="xref-fig-3-10" hwp:rel-id="F3">Figure 3</xref>) or age-dependent stem cell replication treated to adopt absolute replication levels (<xref rid="fig5" ref-type="fig" hwp:id="xref-fig-5-3" hwp:rel-id="F5">Figure 5A,B</xref>). 10 times no replication is still a weak replication. At advanced age, a treatment with a relative improvement of stem cell replication has weak effects on both, the age of organ failure and the shift of cancer risk.</p><p hwp:id="p-36">For organs with intermediate or high turnover (<xref rid="figS3" ref-type="fig" hwp:id="xref-fig-9-2" hwp:rel-id="F9">Supplementary Figure 3</xref>), the original sequence as found in (<xref rid="fig3" ref-type="fig" hwp:id="xref-fig-3-11" hwp:rel-id="F3">Figure 3</xref> and <xref rid="fig5" ref-type="fig" hwp:id="xref-fig-5-4" hwp:rel-id="F5">Figure 5A,B</xref>) is restored, i.e. the later the treatment the more organ failure is retarded. As the sequence of whether treatment of young or old is more advantageous in terms of retardation of organ failure exhibits a switch dependent on the organ turnover level, an turnover rate may exist, at which the treatment effect becomes widely independent of the age of treatment. This is, indeed, the case (<xref rid="figS4" ref-type="fig" hwp:id="xref-fig-10-1" hwp:rel-id="F10">Supplementary Figure 4</xref>). This result suggests that, provided young blood therapy induces a relative increase of stem cell activity, the best age for treatment is different for different organs.</p></sec><sec id="s1f" hwp:id="sec-9"><title hwp:id="title-16">Rejuvenation treatment optimised in mice cannot be transfered to men</title><p hwp:id="p-37">In C57BL/6 mice with a mutation associated with the development of Alzheimer’s disease, parabiosis of young and old mice for 5 weeks could ameliorate cognitive deficits developed in the old mice [<xref ref-type="bibr" rid="c2" hwp:id="xref-ref-2-2" hwp:rel-id="ref-2">2</xref>, <xref ref-type="bibr" rid="c3" hwp:id="xref-ref-3-2" hwp:rel-id="ref-3">3</xref>]. The mathematical model was challenged by testing whether an effect on age of organ failure would be found in this setting. The life expectancy of C57BL/6 mice is in the range of 2 years (see Methods: <italic toggle="yes">Comparison of mouse and human</italic>). The turnover rate of mice organs is substantially higher as suggested by wound healing dynamics. In fact, the model imposes a higher turnover rate (<italic toggle="yes">δ</italic><sub><italic toggle="yes">mouse</italic></sub> <italic toggle="yes">&gt;</italic> 0.4 per year) such that organ failure can happen at the age of two years (see parameters in <xref rid="tbl1" ref-type="table" hwp:id="xref-table-wrap-1-8" hwp:rel-id="T1">Table 1</xref>). In the model with age-dependent loss of stem cell division, a 5 weeks rejuvenation treatment induces a substantial effect on organ failure (<xref rid="fig6" ref-type="fig" hwp:id="xref-fig-6-1" hwp:rel-id="F6">Figure 6A</xref>). In contrast, a 5 weeks treatment of humans had only weak effects even if applied to high turnover organs (<xref rid="fig6" ref-type="fig" hwp:id="xref-fig-6-2" hwp:rel-id="F6">Figure 6B</xref>). This remains also true when applied to a human organ with even higher and unphysiological turnover rates. This implies, that the positive results found in preclinical trials in mice [<xref ref-type="bibr" rid="c3" hwp:id="xref-ref-3-3" hwp:rel-id="ref-3">3</xref>] cannot be expected in human when the same treatment protocol is applied.</p><fig id="fig6" position="float" fig-type="figure" orientation="portrait" hwp:id="F6" hwp:rev-id="xref-fig-6-1 xref-fig-6-2 xref-fig-6-3 xref-fig-6-4 xref-fig-6-5"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;298836v1/FIG6</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F6</object-id><object-id pub-id-type="publisher-id">fig6</object-id><label>Figure 6:</label><caption hwp:id="caption-7"><title hwp:id="title-17">Rejuvenation treatment in mouse and human.</title><p hwp:id="p-38">(<bold>A</bold>) 5-weeks treatment of mice with life expectancy of 2 years in a model with age-dependent degradation of stem cell replication. (<bold>B</bold>) 5-weeks treatment of humans assuming age-dependent degradation of stem cell replication in a high turnover organ. (<bold>C</bold>) 5-weeks treatment of humans with age-independent degradation of stem cell replication (dashed vertical line) in a high turnover organ. The perfect homeostasis replication rate is induced during treatment (full vertical line). (<bold>D</bold>) 2-years treatment of humans with age-dependent degradation of stem cell replication in a low turnover organ. The parameters are taken from <xref rid="tbl1" ref-type="table" hwp:id="xref-table-wrap-1-9" hwp:rel-id="T1">Table 1</xref>. The treatment was assumed to induce absolute renewal rates. For relative improvement see <xref ref-type="fig" rid="figS5" hwp:id="xref-fig-11-1" hwp:rel-id="F11">Supplementary Figure 5</xref>.</p></caption><graphic xlink:href="298836_fig6" position="float" orientation="portrait" hwp:id="graphic-7"/></fig><p hwp:id="p-39">The next question was, under which conditions an effect of the treatment is expected to be detectable in humans. Assuming a lifelong constant stem cell replication in high turnover organs, a 5 weeks rejuvenation treatment (inducing <italic toggle="yes">p</italic><sub><italic toggle="yes">juvenile</italic></sub> in <xref ref-type="disp-formula" rid="eqn11" hwp:id="xref-disp-formula-11-5" hwp:rel-id="disp-formula-11">Eq. (11)</xref>) leads to a substantial improvement (<xref rid="fig6" ref-type="fig" hwp:id="xref-fig-6-3" hwp:rel-id="F6">Figure 6D</xref>). This implies that organs with high turnover and with slow ageing like the skin would benefit from short therapies. In contrast, low turnover organs with ageing stem cells like the brain will only exhibit an effect comparable to the one seen in mice when the treatment is prolonged to the scale of years (<xref rid="fig6" ref-type="fig" hwp:id="xref-fig-6-4" hwp:rel-id="F6">Figure 6D</xref>). Both statement remains true, if one assumes a relative instead of an absolute improvement of stem cell replication (<xref rid="figS5" ref-type="fig" hwp:id="xref-fig-11-2" hwp:rel-id="F11">Supplementary Figure 5</xref>), however, consistently with the results in <xref rid="fig5" ref-type="fig" hwp:id="xref-fig-5-5" hwp:rel-id="F5">Figure 5</xref>, the most advantageous age of treatment is altered.</p></sec></sec><sec id="s2" hwp:id="sec-10"><title hwp:id="title-18">Discussion</title><p hwp:id="p-40">The mathematical analysis of the impact of the transfer of blood from young individuals with the aim to improve stem cell replication predicts that there is an important impact on the delay of organ failure which is payed with a comparably small increase in the risk of developing cancer. The details of improved life time depend on the age of treatment, the turnover rate of the organ, and the mechanism of action of young blood therapy.</p><p hwp:id="p-41">The models with age-dependent and age-independent stem cell replication rate have many properties in common. The larger the turnover rate of the considered organ, the more efficiently organ failure is retarded by small improvements in stem cell replication. However, organ failure cannot be further delayed by stronger treatment, i.e. there is natural limit of retardation of organ failure. In organs with higher turnover rates, cancer risk is stable in response to moderate treatments performed at early age. This bears the chance to really delay organ failure without major risk to induce cancer. However, a conservative dosage of the treatment and a subtle analysis of the biological age of the individual are required. At some biological ages, the treatment can induce an unwanted increase of cancer risk.</p><p hwp:id="p-42">Further, the treatment strategy has to consider the different turnover rates of the different organs. As the treatment is thought to be provided systemically, all organs are equally affected. But the optimum of treatment dosage and treatment age turned out dependent on the organ turnover rate. As a consequence, the treatment has to be chosen in a rather conservative way, such that none of the organs bears an increased cancer risk, but as many of the organs as possible benefit from delayed organ failure.</p><p hwp:id="p-43">The model suggests that the best possible treatment strategy also depends on the mechanistic details of rejuvenation treatment. If the treatment induces an absolute replication rate of stem cells, the age-dependence is similar for all organ turnover rates. However, if the treatment induces an improvement of the replication rate relative to the replication potential of the stem cells at the age of treatment, treatment of older individuals can be without major effect in low turnover organs. Therefore, there is urgent need to clarify the mechanistic details of the effects observed upon rejuvenation therapy [<xref ref-type="bibr" rid="c15" hwp:id="xref-ref-15-1" hwp:rel-id="ref-15">15</xref>].</p><p hwp:id="p-44">In a mouse parabiosis model, improved tissue homeostasis was found in response to 5-weeks treatments [<xref ref-type="bibr" rid="c4" hwp:id="xref-ref-4-2" hwp:rel-id="ref-4">4</xref>, <xref ref-type="bibr" rid="c5" hwp:id="xref-ref-5-2" hwp:rel-id="ref-5">5</xref>]. There is recent evidence that the simple transfer of blood has an impact on tissue homeostasis [<xref ref-type="bibr" rid="c8" hwp:id="xref-ref-8-2" hwp:rel-id="ref-8">8</xref>], which opens the possibility to apply a young blood therapy to humans. According to the model results, the treatment schedule identified in mice with positive effect on tissue homeostasis relies on the higher turnover rate of mouse organs. Therefore, a one-to-one application of the treatment schedule to humans will not induce the same degree of rejuvenation, in particular, in low turnover organs like the brain. Longer treatments in the range of years are required, which shall be considered in the interpretation of the outcome of ongoing clinical trials. A negative outcome would not necessarily imply that rejuvenation of human individuals is not possible by blood derived systemic factors. The code developed here may be used to plan clinical trials and to adapt the treatment schedule to the individual state of organs.</p><p hwp:id="p-45">The strength of the presented analysis relies on the simplicity of the model based exclusively on generic assumptions and parameters determined by plausible side conditions. The analysis suggests that treatment of ageing by young blood transfer has a realistic chance to increase quality of life in the future. However, the treatment exhibits an age- and organ turnover rate-dependent effect and requires a decent planning.</p></sec></body><back><ack hwp:id="ack-1"><title hwp:id="title-19">Acknowledgement</title><p hwp:id="p-46">MMH thanks Georg Pongratz and Rainer Straub for revising the manuscript. MMH was supported by the Helmholtz Initiative on Personalized Medicine (iMED), the German Federal Ministry of Education of Research (eMed: SYSIMIT, SysStomach), and the Human Frontier Science Program (RGP0033/2015).</p></ack><ref-list hwp:id="ref-list-1"><title hwp:id="title-20">References</title><ref id="c1" hwp:id="ref-1" hwp:rev-id="xref-ref-1-1 xref-ref-1-2"><label>1.</label><citation publication-type="journal" citation-type="journal" ref:id="298836v1.1" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-1"><string-name name-style="western" hwp:sortable="DeCarolis N."><surname>DeCarolis</surname>, <given-names>N.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Kirby E."><surname>Kirby</surname>, <given-names>E.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Wyss-Coray T."><surname>Wyss-Coray</surname>, <given-names>T.</given-names></string-name>, and <string-name name-style="western" hwp:sortable="Palmer T."><surname>Palmer</surname>, <given-names>T.</given-names></string-name> <article-title hwp:id="article-title-2">The role of the microenvironmental niche in declining stem-cell functions associated with biological aging</article-title>. <source hwp:id="source-1">Cold Spring Harb Perspect Med</source> <volume>5</volume>, <fpage>a025874</fpage> (<year>2015</year>).</citation></ref><ref id="c2" hwp:id="ref-2" hwp:rev-id="xref-ref-2-1 xref-ref-2-2"><label>2.</label><citation publication-type="journal" citation-type="journal" ref:id="298836v1.2" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-2"><string-name name-style="western" hwp:sortable="Conboy I."><surname>Conboy</surname>, <given-names>I.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Conboy M."><surname>Conboy</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Wagers A."><surname>Wagers</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Girma E."><surname>Girma</surname>, <given-names>E.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Weissman I."><surname>Weissman</surname>, <given-names>I.</given-names></string-name>, and <string-name name-style="western" hwp:sortable="Rando T."><surname>Rando</surname>, <given-names>T.</given-names></string-name> <article-title hwp:id="article-title-3">Rejuvenation of aged progenitor cells by exposure to a young systemic environment</article-title>. <source hwp:id="source-2">Nature</source> <volume>433</volume>, <fpage>760</fpage>–<lpage>764</lpage> (<year>2005</year>).</citation></ref><ref id="c3" hwp:id="ref-3" hwp:rev-id="xref-ref-3-1 xref-ref-3-2 xref-ref-3-3"><label>3.</label><citation publication-type="journal" citation-type="journal" ref:id="298836v1.3" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-3"><string-name name-style="western" hwp:sortable="Middeldorp J."><surname>Middeldorp</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Lehallier B."><surname>Lehallier</surname>, <given-names>B.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Villeda S."><surname>Villeda</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Miedema S."><surname>Miedema</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Evans E."><surname>Evans</surname>, <given-names>E.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Czirr E."><surname>Czirr</surname>, <given-names>E.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Zhang H."><surname>Zhang</surname>, <given-names>H.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Luo J."><surname>Luo</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Stan T."><surname>Stan</surname>, <given-names>T.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Mosher K."><surname>Mosher</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Masliah E."><surname>Masliah</surname>, <given-names>E.</given-names></string-name>, and <string-name name-style="western" hwp:sortable="Wyss-Coray T."><surname>Wyss-Coray</surname>, <given-names>T.</given-names></string-name> <article-title hwp:id="article-title-4">Preclinical assessment of young blood plasma for Alzheimer disease</article-title>. <source hwp:id="source-3">JAMA Neurol</source> <volume>73</volume>(<issue>11</issue>), <fpage>1325</fpage>–<lpage>1333</lpage> (<year>2016</year>).</citation></ref><ref id="c4" hwp:id="ref-4" hwp:rev-id="xref-ref-4-1 xref-ref-4-2"><label>4.</label><citation publication-type="journal" citation-type="journal" ref:id="298836v1.4" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-4"><string-name name-style="western" hwp:sortable="Conboy M."><surname>Conboy</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Conboy I."><surname>Conboy</surname>, <given-names>I.</given-names></string-name>, and <string-name name-style="western" hwp:sortable="Rando T."><surname>Rando</surname>, <given-names>T.</given-names></string-name> <article-title hwp:id="article-title-5">Hereochronic parabiosis: historical perspective and methodological considerations for studies of aging and longevity</article-title>. <source hwp:id="source-4">Aging Cell</source> <volume>12</volume>, <fpage>525</fpage>–<lpage>530</lpage> (<year>2013</year>).</citation></ref><ref id="c5" hwp:id="ref-5" hwp:rev-id="xref-ref-5-1 xref-ref-5-2"><label>5.</label><citation publication-type="journal" citation-type="journal" ref:id="298836v1.5" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-5"><string-name name-style="western" hwp:sortable="Castellano J."><surname>Castellano</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Palner M."><surname>Palner</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Li S.-B."><surname>Li</surname>, <given-names>S.-B.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Freeman Jr G."><surname>Freeman Jr</surname>, <given-names>G.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Nguyen A."><surname>Nguyen</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Shen B."><surname>Shen</surname>, <given-names>B.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Stan T."><surname>Stan</surname>, <given-names>T.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Mosher K."><surname>Mosher</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Chin F."><surname>Chin</surname>, <given-names>F.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Lecea L. d."><surname>Lecea</surname>, <given-names>L. d.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Luo J."><surname>Luo</surname>, <given-names>J.</given-names></string-name>, and <string-name name-style="western" hwp:sortable="Wyss-Coray T."><surname>Wyss-Coray</surname>, <given-names>T.</given-names></string-name> <article-title hwp:id="article-title-6">In vivo assessment of behavioral recovery and circulatory exchange in the peritoneal parabiosis model</article-title>. <source hwp:id="source-5">Sci Rep</source> <volume>6</volume>, <fpage>29015</fpage> (<year>2016</year>).</citation></ref><ref id="c6" hwp:id="ref-6" hwp:rev-id="xref-ref-6-1"><label>6.</label><citation publication-type="journal" citation-type="journal" ref:id="298836v1.6" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-6"><string-name name-style="western" hwp:sortable="Castellano J."><surname>Castellano</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Kirby E."><surname>Kirby</surname>, <given-names>E.</given-names></string-name>, and <string-name name-style="western" hwp:sortable="Wyss-Coray T."><surname>Wyss-Coray</surname>, <given-names>T.</given-names></string-name> <article-title hwp:id="article-title-7">Blood-borne revitalization of the aged brain</article-title>. <source hwp:id="source-6">JAMA Neurol</source> <volume>72</volume>(<issue>10</issue>), <fpage>1191</fpage>–<lpage>1194</lpage> (<year>2015</year>).</citation></ref><ref id="c7" hwp:id="ref-7" hwp:rev-id="xref-ref-7-1"><label>7.</label><citation publication-type="journal" citation-type="journal" ref:id="298836v1.7" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-7"><string-name name-style="western" hwp:sortable="Wyss-Coray T."><surname>Wyss-Coray</surname>, <given-names>T.</given-names></string-name> <article-title hwp:id="article-title-8">Ageing, neurodegeneration and brain rejuvenation</article-title>. <source hwp:id="source-7">Nature</source> <volume>539</volume>(<issue>7628</issue>), <fpage>180</fpage>–<lpage>186</lpage> (<year>2016</year>).</citation></ref><ref id="c8" hwp:id="ref-8" hwp:rev-id="xref-ref-8-1 xref-ref-8-2"><label>8.</label><citation publication-type="journal" citation-type="journal" ref:id="298836v1.8" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-8"><string-name name-style="western" hwp:sortable="Rebo J."><surname>Rebo</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Mehdipour M."><surname>Mehdipour</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Gathwala R."><surname>Gathwala</surname>, <given-names>R.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Causey K."><surname>Causey</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Liu Y."><surname>Liu</surname>, <given-names>Y.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Conboy M."><surname>Conboy</surname>, <given-names>M.</given-names></string-name>, and <string-name name-style="western" hwp:sortable="Conboy I."><surname>Conboy</surname>, <given-names>I.</given-names></string-name> <article-title hwp:id="article-title-9">A single heterochronic blood exchange reveals rapid inhibition of multiple tissues by old blood</article-title>. <source hwp:id="source-8">Nat Commun</source> <volume>7</volume>, <fpage>13363</fpage> (<year>2016</year>).</citation></ref><ref id="c9" hwp:id="ref-9" hwp:rev-id="xref-ref-9-1"><label>9.</label><citation publication-type="journal" citation-type="journal" ref:id="298836v1.9" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-9"><string-name name-style="western" hwp:sortable="Stratton M."><surname>Stratton</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Campbell P."><surname>Campbell</surname>, <given-names>P.</given-names></string-name>, and <string-name name-style="western" hwp:sortable="Futreal P."><surname>Futreal</surname>, <given-names>P.</given-names></string-name> <article-title hwp:id="article-title-10">The cancer genome</article-title>. <source hwp:id="source-9">Nature Reviews</source> <volume>458</volume>, <fpage>719</fpage>–<lpage>724</lpage> (<year>2009</year>).</citation></ref><ref id="c10" hwp:id="ref-10" hwp:rev-id="xref-ref-10-1"><label>10.</label><citation publication-type="journal" citation-type="journal" ref:id="298836v1.10" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-10"><string-name name-style="western" hwp:sortable="Blokzijl F."><surname>Blokzijl</surname>, <given-names>F.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ligt J. d."><surname>Ligt</surname>, <given-names>J. d.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Jager M."><surname>Jager</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Sasselli V."><surname>Sasselli</surname>, <given-names>V.</given-names></string-name>, and <string-name name-style="western" hwp:sortable="Roerink S. e. a."><surname>Roerink</surname>, <given-names>S. e. a.</given-names></string-name> <article-title hwp:id="article-title-11">Tissue-specific mutation accumulation in human adult stem cells during life</article-title>. <source hwp:id="source-10">Nature</source> <volume>538</volume>, <fpage>260</fpage>–<lpage>264</lpage> (<year>2016</year>).</citation></ref><ref id="c11" hwp:id="ref-11" hwp:rev-id="xref-ref-11-1"><label>11.</label><citation publication-type="journal" citation-type="journal" ref:id="298836v1.11" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-11"><string-name name-style="western" hwp:sortable="Tomasetti C."><surname>Tomasetti</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Li L."><surname>Li</surname>, <given-names>L.</given-names></string-name>, and <string-name name-style="western" hwp:sortable="Vogelstein B."><surname>Vogelstein</surname>, <given-names>B.</given-names></string-name> <article-title hwp:id="article-title-12">Stem cell divisions, somatic mutations, cancer etiology, and cancer prevention</article-title>. <source hwp:id="source-11">Science</source> <volume>355</volume>, <fpage>1330</fpage>–<lpage>1334</lpage> (<year>2017</year>).</citation></ref><ref id="c12" hwp:id="ref-12" hwp:rev-id="xref-ref-12-1"><label>12.</label><citation publication-type="journal" citation-type="journal" ref:id="298836v1.12" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-12"><string-name name-style="western" hwp:sortable="Giangreco A."><surname>Giangreco</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Qin M."><surname>Qin</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Pintar J."><surname>Pintar</surname>, <given-names>J.</given-names></string-name>, and <string-name name-style="western" hwp:sortable="Watt F."><surname>Watt</surname>, <given-names>F.</given-names></string-name> <article-title hwp:id="article-title-13">Epidermal stem cells are retained in vivo throughout skin aging</article-title>. <source hwp:id="source-12">Aging Cell</source> <volume>7</volume>, <fpage>250</fpage>–<lpage>259</lpage> (<year>2008</year>).</citation></ref><ref id="c13" hwp:id="ref-13" hwp:rev-id="xref-ref-13-1"><label>13.</label><citation publication-type="journal" citation-type="journal" ref:id="298836v1.13" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-13"><string-name name-style="western" hwp:sortable="Sudo K."><surname>Sudo</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ema H."><surname>Ema</surname>, <given-names>H.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Morita Y."><surname>Morita</surname>, <given-names>Y.</given-names></string-name>, and <string-name name-style="western" hwp:sortable="Nakauchi H."><surname>Nakauchi</surname>, <given-names>H.</given-names></string-name> <article-title hwp:id="article-title-14">Age-associated characteristics of murine hematopoietic stem cells</article-title>. <source hwp:id="source-13">J Exp Med</source> <volume>192</volume>, <fpage>1273</fpage>–<lpage>1280</lpage> (<year>2000</year>).</citation></ref><ref id="c14" hwp:id="ref-14" hwp:rev-id="xref-ref-14-1"><label>14.</label><citation publication-type="journal" citation-type="journal" ref:id="298836v1.14" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-14"><string-name name-style="western" hwp:sortable="Dykstra B."><surname>Dykstra</surname>, <given-names>B.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Olthof S."><surname>Olthof</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Schreuder J."><surname>Schreuder</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ritsema M."><surname>Ritsema</surname>, <given-names>M.</given-names></string-name>, and <string-name name-style="western" hwp:sortable="Haan G. d."><surname>Haan</surname>, <given-names>G. d.</given-names></string-name> <article-title hwp:id="article-title-15">Clonal analysis reveals multiple functional defects of aged murine hematopoietic stem cells</article-title>. <source hwp:id="source-14">J Exp Med</source> <volume>208</volume>, <fpage>2691</fpage>–<lpage>2703</lpage> (<year>2011</year>).</citation></ref><ref id="c15" hwp:id="ref-15" hwp:rev-id="xref-ref-15-1"><label>15.</label><citation publication-type="journal" citation-type="journal" ref:id="298836v1.15" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-15"><string-name name-style="western" hwp:sortable="Brunet A."><surname>Brunet</surname>, <given-names>A.</given-names></string-name> and <string-name name-style="western" hwp:sortable="Rando T."><surname>Rando</surname>, <given-names>T.</given-names></string-name> <article-title hwp:id="article-title-16">Interaction between epigenetic and metabolism in aging stem cells</article-title>. <source hwp:id="source-15">Curr Opin Cell Biol</source> <volume>45</volume>, <fpage>1</fpage>–<lpage>7</lpage> (<year>2017</year>).</citation></ref><ref id="c16" hwp:id="ref-16" hwp:rev-id="xref-ref-16-1"><label>16.</label><citation publication-type="journal" citation-type="journal" ref:id="298836v1.16" ref:linkable="no" ref:use-reference-as-is="yes" hwp:id="citation-16"><string-name name-style="western" hwp:sortable="Graber T."><surname>Graber</surname>, <given-names>T.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Kim J.-H."><surname>Kim</surname>, <given-names>J.-H.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Grange R."><surname>Grange</surname>, <given-names>R.</given-names></string-name>, <string-name name-style="western" hwp:sortable="McLoon L."><surname>McLoon</surname>, <given-names>L.</given-names></string-name>, and <string-name name-style="western" hwp:sortable="Thompson L."><surname>Thompson</surname>, <given-names>L.</given-names></string-name> <article-title hwp:id="article-title-17">C57BL/6 life span study: age-related declines in muscle power production and contractile velocity</article-title>. <source hwp:id="source-16">Age</source> <volume>37</volume>, <issue>9773</issue> (<year>2015</year>).</citation></ref></ref-list><sec id="s3" hwp:id="sec-11"><title hwp:id="title-21">Author contribution</title><p hwp:id="p-47">MMH developed the research idea and the approach, programmed the code, interpreted the results and wrote the manuscript.</p></sec><sec id="s4" hwp:id="sec-12"><title hwp:id="title-22">Methods</title><sec id="s4a" hwp:id="sec-13"><title hwp:id="title-23">Model equations and analytical solution</title><p hwp:id="p-48">The model of tissue homeostasis distinguishes stem cells <italic toggle="yes">S</italic> and tissue cells <italic toggle="yes">T</italic>. Each cell type is classified by the number of accumulated damages with an index <italic toggle="yes">i</italic> for both quantities, i.e. <italic toggle="yes">S</italic><sub><italic toggle="yes">i</italic></sub> and <italic toggle="yes">T</italic><sub><italic toggle="yes">i</italic></sub>. Model assumptions are described in the main text. The set of ordinary differential equations reads
<disp-formula id="eqn1" hwp:id="disp-formula-1" hwp:rev-id="xref-disp-formula-1-1 xref-disp-formula-1-2 xref-disp-formula-1-3 xref-disp-formula-1-4 xref-disp-formula-1-5 xref-disp-formula-1-6 xref-disp-formula-1-7">
<alternatives hwp:id="alternatives-1"><graphic xlink:href="298836_eqn1.gif" position="float" orientation="portrait" hwp:id="graphic-8"/></alternatives>
</disp-formula>
 with initial values <italic toggle="yes">S</italic><sub><italic toggle="yes">i</italic></sub>(<italic toggle="yes">t</italic><sub>0</sub>) = <italic toggle="yes">σ</italic><sub><italic toggle="yes">i</italic></sub> and <italic toggle="yes">T</italic><sub><italic toggle="yes">i</italic></sub>(<italic toggle="yes">t</italic><sub>0</sub>) = <italic toggle="yes">τ</italic><sub><italic toggle="yes">i</italic></sub>. <italic toggle="yes">p</italic> is the stem cell replication rate, <italic toggle="yes">γ</italic> is the cell damage rate, and <italic toggle="yes">δ</italic> is the death rate of tissue cells, which corresponds to the turnover rate of the considered organ.</p><p hwp:id="p-49">The analytical solution of the model <xref ref-type="disp-formula" rid="eqn1" hwp:id="xref-disp-formula-1-3" hwp:rel-id="disp-formula-1">Eq. (1)</xref>
<disp-formula id="eqn2" hwp:id="disp-formula-2" hwp:rev-id="xref-disp-formula-2-1 xref-disp-formula-2-2 xref-disp-formula-2-3 xref-disp-formula-2-4 xref-disp-formula-2-5 xref-disp-formula-2-6 xref-disp-formula-2-7 xref-disp-formula-2-8 xref-disp-formula-2-9 xref-disp-formula-2-10 xref-disp-formula-2-11 xref-disp-formula-2-12 xref-disp-formula-2-13 xref-disp-formula-2-14">
<alternatives hwp:id="alternatives-2"><graphic xlink:href="298836_eqn2.gif" position="float" orientation="portrait" hwp:id="graphic-9"/></alternatives>
</disp-formula>
can be proven by complete induction (see Methods: <italic toggle="yes">Proof of the analytical solution</italic>). In the limit of no damage by mutations (i.e. <italic toggle="yes">γ</italic> = 0), the division rate <italic toggle="yes">p</italic> can be determined by the condition of organ failure at the age of Θ = 80 years (see Methods: <italic toggle="yes">Determination of the division rate</italic>). The mutation frequency <italic toggle="yes">γ</italic> is determined by the side condition that the risk of cancer is <italic toggle="yes">ξ</italic> = 30% at the age of Θ = 80 years (see Methods: <italic toggle="yes">Determination of the mutation rate</italic>).</p><p hwp:id="p-50"><italic toggle="yes">m</italic> is the maximum number of damages explicitly calculated, with <italic toggle="yes">m</italic> ≫ <italic toggle="yes">c</italic>. Stem and tissue cells with <italic toggle="yes">c</italic> or more accumulated damage are recollected for presentation as
<disp-formula id="eqn3" hwp:id="disp-formula-3">
<alternatives hwp:id="alternatives-3"><graphic xlink:href="298836_eqn3.gif" position="float" orientation="portrait" hwp:id="graphic-10"/></alternatives>
</disp-formula>
where <italic toggle="yes">m</italic> = 3<italic toggle="yes">c</italic> is chosen sufficiently large such that the results are independent of <italic toggle="yes">m</italic>.</p></sec><sec id="s4b" hwp:id="sec-14"><title hwp:id="title-24">Determination of the division rate</title><p hwp:id="p-51">The division rate <italic toggle="yes">p</italic> can be fixed by the condition that organ failure happens at the age of Θ. Organ failure is assumed to happen when the initial number of tissue cells drops below a fraction <italic toggle="yes">f</italic> = 0.5. It is assumed independent of the number of mutations, thus, <xref ref-type="disp-formula" rid="eqn1" hwp:id="xref-disp-formula-1-4" hwp:rel-id="disp-formula-1">Eq. (1)</xref> can be solved in the limit of no mutations, i.e. <italic toggle="yes">γ</italic> = 0, which reduces all equations to those indexed with 0. The differential equations for stem and tissue cells read:
<disp-formula id="eqn4" hwp:id="disp-formula-4">
<alternatives hwp:id="alternatives-4"><graphic xlink:href="298836_eqn4.gif" position="float" orientation="portrait" hwp:id="graphic-11"/></alternatives>
</disp-formula>
where <italic toggle="yes">S</italic> = <italic toggle="yes">σ</italic><sub>0</sub> = <italic toggle="yes">const</italic>. Separation of variables, integration and incorporation of the death condition yields
<disp-formula id="eqn5" hwp:id="disp-formula-5">
<alternatives hwp:id="alternatives-5"><graphic xlink:href="298836_eqn5.gif" position="float" orientation="portrait" hwp:id="graphic-12"/></alternatives>
</disp-formula>
for the unknown division rate <italic toggle="yes">p</italic><sub><italic toggle="yes">normal</italic></sub>. This can be solved for the division rate <italic toggle="yes">p</italic><sub><italic toggle="yes">normal</italic></sub> resulting in
<disp-formula id="eqn6" hwp:id="disp-formula-6" hwp:rev-id="xref-disp-formula-6-1 xref-disp-formula-6-2 xref-disp-formula-6-3">
<alternatives hwp:id="alternatives-6"><graphic xlink:href="298836_eqn6.gif" position="float" orientation="portrait" hwp:id="graphic-13"/></alternatives>
</disp-formula>
The division rate determined by <xref ref-type="disp-formula" rid="eqn6" hwp:id="xref-disp-formula-6-3" hwp:rel-id="disp-formula-6">Eq. (6)</xref> is used to set up the dynamics of stem cell division and tissue renewal in normal life without any treatment.</p></sec><sec id="s4c" hwp:id="sec-15"><title hwp:id="title-25">Determination of the mutation rate</title><p hwp:id="p-52">The mutation rate <italic toggle="yes">γ</italic> is determined by the cancer risk <italic toggle="yes">ξ</italic> at the age of life expectancy Θ, where cancer is induced at <italic toggle="yes">c</italic> mutations. Assuming no damage at birth and ignoring more than <italic toggle="yes">c</italic> mutations this condition translates to
<disp-formula id="eqn7" hwp:id="disp-formula-7" hwp:rev-id="xref-disp-formula-7-1">
<alternatives hwp:id="alternatives-7"><graphic xlink:href="298836_eqn7.gif" position="float" orientation="portrait" hwp:id="graphic-14"/></alternatives>
</disp-formula>
This can be reformulated as
<disp-formula id="eqn8" hwp:id="disp-formula-8">
<alternatives hwp:id="alternatives-8"><graphic xlink:href="298836_eqn8.gif" position="float" orientation="portrait" hwp:id="graphic-15"/></alternatives>
</disp-formula>
An implicit equation for <italic toggle="yes">γ</italic> of this type is solved by a Lambert W-function as
<disp-formula id="eqn9" hwp:id="disp-formula-9" hwp:rev-id="xref-disp-formula-9-1">
<alternatives hwp:id="alternatives-9"><graphic xlink:href="298836_eqn9.gif" position="float" orientation="portrait" hwp:id="graphic-16"/></alternatives>
</disp-formula>
This solution is just an upper bound for <italic toggle="yes">γ</italic> because all contributions of cells with more than <italic toggle="yes">c</italic> mutations were ignored. The condition <xref ref-type="disp-formula" rid="eqn7" hwp:id="xref-disp-formula-7-1" hwp:rel-id="disp-formula-7">Eq. (7)</xref> with all contributions from cells with <italic toggle="yes">c</italic> or more mutations reads
<disp-formula id="eqn10" hwp:id="disp-formula-10">
<alternatives hwp:id="alternatives-10"><graphic xlink:href="298836_eqn10.gif" position="float" orientation="portrait" hwp:id="graphic-17"/></alternatives>
</disp-formula>
This equation is numerically solved for <italic toggle="yes">γ</italic> where <xref ref-type="disp-formula" rid="eqn9" hwp:id="xref-disp-formula-9-1" hwp:rel-id="disp-formula-9">Eq. (9)</xref> is used as an initial guess and upper bound.</p></sec><sec id="s4d" hwp:id="sec-16"><title hwp:id="title-26">Determination of the division rate of perfect homeostasis</title><p hwp:id="p-53">Perfect homeostasis implies that any loss of tissue cells by the term <italic toggle="yes">δT</italic><sub><italic toggle="yes">i</italic></sub> in <xref ref-type="disp-formula" rid="eqn1" hwp:id="xref-disp-formula-1-5" hwp:rel-id="disp-formula-1">Eq. (1)</xref> is compensated by stem cell division with the term <italic toggle="yes">pS</italic><sub><italic toggle="yes">i</italic></sub>. As this has to happen for all damage levels <italic toggle="yes">i</italic>, it is possible to just consider the sum of all cells, which leads to the condition
<disp-formula id="eqn11" hwp:id="disp-formula-11" hwp:rev-id="xref-disp-formula-11-1 xref-disp-formula-11-2 xref-disp-formula-11-3 xref-disp-formula-11-4 xref-disp-formula-11-5 xref-disp-formula-11-6">
<alternatives hwp:id="alternatives-11"><graphic xlink:href="298836_eqn11.gif" position="float" orientation="portrait" hwp:id="graphic-18"/></alternatives>
</disp-formula>
When <italic toggle="yes">p</italic> = <italic toggle="yes">p</italic><sub><italic toggle="yes">juvenile</italic></sub> for the whole life, organ failure never happens.</p></sec><sec id="s4e" hwp:id="sec-17"><title hwp:id="title-27">Calculation of the age of cancer risk <italic toggle="yes">ξ</italic></title><p hwp:id="p-54">Given the cancer risk <italic toggle="yes">ξ</italic> and the constant division rate <italic toggle="yes">p</italic>, it is informative to calculate the age Θ<sub><italic toggle="yes">c</italic></sub>(<italic toggle="yes">p</italic>), at which the cancer risk reaches <italic toggle="yes">ξ</italic>. This age can be determined from the condition
<disp-formula id="eqn12" hwp:id="disp-formula-12" hwp:rev-id="xref-disp-formula-12-1 xref-disp-formula-12-2 xref-disp-formula-12-3">
<alternatives hwp:id="alternatives-12"><graphic xlink:href="298836_eqn12.gif" position="float" orientation="portrait" hwp:id="graphic-19"/></alternatives>
</disp-formula>
This condition has to be solved for Θ<sub><italic toggle="yes">c</italic></sub>(<italic toggle="yes">p</italic>), which was done by numerical approximation of the zero of <xref ref-type="disp-formula" rid="eqn12" hwp:id="xref-disp-formula-12-3" hwp:rel-id="disp-formula-12">Eq. (12)</xref>. The relationship is shown in <xref rid="fig2" ref-type="fig" hwp:id="xref-fig-2-4" hwp:rel-id="F2">Figure 2</xref> (blue line).</p></sec><sec id="s4f" hwp:id="sec-18"><title hwp:id="title-28">Calculation of the age of organ failure</title><p hwp:id="p-55">Given the division rate <italic toggle="yes">p</italic> and the initial stem and tissue cell numbers <italic toggle="yes">σ</italic><sub>0</sub> and <italic toggle="yes">τ</italic><sub>0</sub> it is informative to calculate the age Θ<sub><italic toggle="yes">f</italic></sub>(<italic toggle="yes">p</italic>), at which the total tissue cell numbers hit the fraction <italic toggle="yes">f τ</italic><sub>0</sub> of organ failure. As the distribution of tissue cells on classes with different levels of accumulated damages does not matter, the condition for organ failure can be calculated in the limit of no damage <italic toggle="yes">γ</italic> = 0. Starting from the analytical solution <xref ref-type="disp-formula" rid="eqn2" hwp:id="xref-disp-formula-2-3" hwp:rel-id="disp-formula-2">Eq. (2)</xref>, the condition reads
<disp-formula id="eqn13" hwp:id="disp-formula-13" hwp:rev-id="xref-disp-formula-13-1">
<alternatives hwp:id="alternatives-13"><graphic xlink:href="298836_eqn13.gif" position="float" orientation="portrait" hwp:id="graphic-20"/></alternatives>
</disp-formula>
which is solved by
<disp-formula id="eqn14" hwp:id="disp-formula-14" hwp:rev-id="xref-disp-formula-14-1 xref-disp-formula-14-2 xref-disp-formula-14-3">
<alternatives hwp:id="alternatives-14"><graphic xlink:href="298836_eqn14.gif" position="float" orientation="portrait" hwp:id="graphic-21"/></alternatives>
</disp-formula>
Note that for larger division rates, a physiological solution does not exist in the sense of the argument of the logarithm becoming negative. This relationship is shown in <xref rid="fig2" ref-type="fig" hwp:id="xref-fig-2-5" hwp:rel-id="F2">Figure 2</xref> (red line).</p></sec><sec id="s4g" hwp:id="sec-19"><title hwp:id="title-29">Treatment at particular ages</title><p hwp:id="p-56">When the <italic toggle="yes">k</italic>-th treatment with young blood is initiated at a particular age <italic toggle="yes">t</italic><sub><italic toggle="yes">k</italic></sub> of the individual, the division rate <italic toggle="yes">p</italic> is changed at this particular age. This implies that the cell damage distribution <inline-formula hwp:id="inline-formula-1"><alternatives hwp:id="alternatives-15"><inline-graphic xlink:href="298836_inline1.gif" hwp:id="inline-graphic-1"/></alternatives></inline-formula> for <italic toggle="yes">i</italic> ∈ [0<italic toggle="yes">, m</italic>]} calculated by the time <italic toggle="yes">t</italic><sub><italic toggle="yes">k</italic></sub> was used as initial condition for the solution <xref ref-type="disp-formula" rid="eqn2" hwp:id="xref-disp-formula-2-4" hwp:rel-id="disp-formula-2">Eq. (2)</xref>. The development for times <italic toggle="yes">t &gt; t</italic><sub><italic toggle="yes">k</italic></sub> are then calculated from <xref ref-type="disp-formula" rid="eqn2" hwp:id="xref-disp-formula-2-5" hwp:rel-id="disp-formula-2">Eq. (2)</xref> with initial condition <inline-formula hwp:id="inline-formula-2"><alternatives hwp:id="alternatives-16"><inline-graphic xlink:href="298836_inline2.gif" hwp:id="inline-graphic-2"/></alternatives></inline-formula>, with <italic toggle="yes">t</italic><sub>0</sub> = <italic toggle="yes">t</italic><sub><italic toggle="yes">k</italic></sub>, and with the changed <italic toggle="yes">p</italic>. When <italic toggle="yes">p</italic> is changed again, the same procedure has to be repeated. This remains true irrespective of whether the analytical solution <xref ref-type="disp-formula" rid="eqn2" hwp:id="xref-disp-formula-2-6" hwp:rel-id="disp-formula-2">Eq. (2)</xref> or the numerical solution with age-dependent <italic toggle="yes">p</italic> is used.</p></sec><sec id="s4h" hwp:id="sec-20"><title hwp:id="title-30">Age-dependent stem cell division rate</title><p hwp:id="p-57">Depending on the considered organ, stem cell replication is lost with increasing age. An age-dependent reduction of stem cell replication <italic toggle="yes">p</italic>(<italic toggle="yes">t</italic>) was introduced by replacing each occurrence of <italic toggle="yes">p</italic> in <xref ref-type="disp-formula" rid="eqn1" hwp:id="xref-disp-formula-1-6" hwp:rel-id="disp-formula-1">Eq. (1)</xref> by <italic toggle="yes">p</italic>(<italic toggle="yes">t</italic>). The solution <xref ref-type="disp-formula" rid="eqn2" hwp:id="xref-disp-formula-2-7" hwp:rel-id="disp-formula-2">Eq. (2)</xref> is not valid anymore and this system was solved numerically. A Hill-function was used to describe natural loss of stem cell replication as
<disp-formula id="eqn15" hwp:id="disp-formula-15" hwp:rev-id="xref-disp-formula-15-1 xref-disp-formula-15-2 xref-disp-formula-15-3 xref-disp-formula-15-4 xref-disp-formula-15-5">
<alternatives hwp:id="alternatives-17"><graphic xlink:href="298836_eqn15.gif" position="float" orientation="portrait" hwp:id="graphic-22"/></alternatives>
</disp-formula>
with the replication rate at birth <italic toggle="yes">p</italic><sub><italic toggle="yes">max</italic></sub> = <italic toggle="yes">p</italic>(<italic toggle="yes">t</italic> = 0) = <italic toggle="yes">p</italic><sub><italic toggle="yes">juvenile</italic></sub> determined from the assumption of perfect homeostasis <xref ref-type="disp-formula" rid="eqn11" hwp:id="xref-disp-formula-11-6" hwp:rel-id="disp-formula-11">Eq. (11)</xref>. The Hill-coefficient is set to <italic toggle="yes">n</italic> = 2. The age of half replication <italic toggle="yes">K</italic> was chosen such that organ failure occurs at age Θ.</p></sec><sec id="s4i" hwp:id="sec-21"><title hwp:id="title-31">Comparison of mouse and human</title><p hwp:id="p-58">The life expectancy of mice is in the range of two years [<xref ref-type="bibr" rid="c16" hwp:id="xref-ref-16-1" hwp:rel-id="ref-16">16</xref>]. With the organ turnover rates <italic toggle="yes">δ</italic> for humans (see <xref rid="tbl1" ref-type="table" hwp:id="xref-table-wrap-1-10" hwp:rel-id="T1">Table 1</xref>), organ failure at the age of two years cannot be induced in the model (see <xref ref-type="disp-formula" rid="eqn13" hwp:id="xref-disp-formula-13-1" hwp:rel-id="disp-formula-13">Eq. (13)</xref>). Substantially higher turnover rates with <italic toggle="yes">δ &gt;</italic> 0.4 per year are required to get a solution of the model with positive division rates <italic toggle="yes">p</italic>. At such high turnover rates, organ failure at the age of human life expectancy Θ = 80 years is not achieved (see Eqs. (6) and (13)).</p></sec><sec id="s4j" hwp:id="sec-22"><title hwp:id="title-32">Robustness of the statements</title><p hwp:id="p-59">The sensitivity of the results to changes in the parameter values used in <xref rid="tbl1" ref-type="table" hwp:id="xref-table-wrap-1-11" hwp:rel-id="T1">Table 1</xref> and in <xref ref-type="disp-formula" rid="eqn15" hwp:id="xref-disp-formula-15-3" hwp:rel-id="disp-formula-15">Eq. (15)</xref> is analysed.</p><p hwp:id="p-60">The number of mutations per cell associated with induction of cancer <italic toggle="yes">c</italic> was chosen arbi-trarily as <italic toggle="yes">c</italic> = 10. For very low <italic toggle="yes">c</italic> the system gets unstable. For larger <italic toggle="yes">c</italic> the behaviour and all described results remain qualitatively unchanged. There is strictly no impact of <italic toggle="yes">c</italic> on the age of organ failure. The impact of treatment on the age of cancer risk <italic toggle="yes">ξ</italic> is further reduced for larger values of <italic toggle="yes">c</italic> (see <xref rid="figS6" ref-type="fig" hwp:id="xref-fig-12-1" hwp:rel-id="F12">Supplementary Figure 6</xref>). The results based on <italic toggle="yes">c</italic> = 10 can be considered as an upper limit for the increase in cancer risk, as the number of mutations inducing cancer is likely not smaller than 10 but for extreme cases.</p><p hwp:id="p-61">Larger <italic toggle="yes">n</italic> in <xref ref-type="disp-formula" rid="eqn15" hwp:id="xref-disp-formula-15-4" hwp:rel-id="disp-formula-15">Eq. (15)</xref> reduces while smaller <italic toggle="yes">n</italic> increases the overall effect on both, the ages of organ failure and cancer risk <italic toggle="yes">ξ</italic>, in particular, for late treatments (see <xref ref-type="fig" rid="figS7" hwp:id="xref-fig-13-1" hwp:rel-id="F13">Supplementary Figure 7</xref>). This is consistent with the observation that in the extreme case of constant <italic toggle="yes">p</italic> the effect was larger as well (see <xref rid="fig3" ref-type="fig" hwp:id="xref-fig-3-12" hwp:rel-id="F3">Figure 3</xref>). A determination of the stem cell activity in human organs over life would allow for a more concrete attribution of therapy effects <italic toggle="yes">in silico</italic> to human organs.</p><p hwp:id="p-62">A change in the relative proportion of stem cells <italic toggle="yes">σ</italic><sub>0</sub> and tissue cells <italic toggle="yes">τ</italic><sub>0</sub> has strictly no influence on the results (see <xref ref-type="fig" rid="figS8" hwp:id="xref-fig-14-1" hwp:rel-id="F14">Supplementary Figure 8</xref>). The stem cell division rate, by construction, compensates for a different fraction of stem cells. However, the association of the virtual turnover rates with real tissues turnover rates changes.</p></sec><sec id="s4k" hwp:id="sec-23"><title hwp:id="title-33">Proof of the analytical solution</title><p hwp:id="p-63">The ordinary differential equation system <xref ref-type="disp-formula" rid="eqn1" hwp:id="xref-disp-formula-1-7" hwp:rel-id="disp-formula-1">Eq. (1)</xref> can be solved analytically (see <xref ref-type="disp-formula" rid="eqn2" hwp:id="xref-disp-formula-2-8" hwp:rel-id="disp-formula-2">Eq. (2)</xref>). The solution can be proven by complete induction, which is sketched here. For the stem cell compartment <italic toggle="yes">S</italic><sub><italic toggle="yes">i</italic></sub> with <italic toggle="yes">i</italic> ≥ 0 the base case is explicitly calculated. The solutions for <italic toggle="yes">S</italic><sub>0,1</sub> are trivial. Let us assume that the general solution <xref ref-type="disp-formula" rid="eqn2" hwp:id="xref-disp-formula-2-9" hwp:rel-id="disp-formula-2">Eq. (2)</xref> is valid for <italic toggle="yes">S</italic><sub><italic toggle="yes">i</italic></sub>. Then
<disp-formula id="eqn16" hwp:id="disp-formula-16" hwp:rev-id="xref-disp-formula-16-1">
<alternatives hwp:id="alternatives-18"><graphic xlink:href="298836_eqn16.gif" position="float" orientation="portrait" hwp:id="graphic-23"/></alternatives>
</disp-formula>
A differential equation of the form
<disp-formula id="eqn17" hwp:id="disp-formula-17">
<alternatives hwp:id="alternatives-19"><graphic xlink:href="298836_eqn17.gif" position="float" orientation="portrait" hwp:id="graphic-24"/></alternatives>
</disp-formula>
is solved by
<disp-formula id="eqn18" hwp:id="disp-formula-18" hwp:rev-id="xref-disp-formula-18-1 xref-disp-formula-18-2">
<alternatives hwp:id="alternatives-20"><graphic xlink:href="298836_eqn18.gif" position="float" orientation="portrait" hwp:id="graphic-25"/></alternatives>
</disp-formula>
where <italic toggle="yes">A</italic> is a primitive of <italic toggle="yes">a</italic> and <italic toggle="yes">c</italic> is an integration constant. In the case of <xref ref-type="disp-formula" rid="eqn16" hwp:id="xref-disp-formula-16-1" hwp:rel-id="disp-formula-16">Eq. (16)</xref>, we have
<disp-formula id="eqn19" hwp:id="disp-formula-19">
<alternatives hwp:id="alternatives-21"><graphic xlink:href="298836_eqn19.gif" position="float" orientation="portrait" hwp:id="graphic-26"/></alternatives>
</disp-formula>
where <italic toggle="yes">S</italic><sub><italic toggle="yes">i</italic></sub> is taken from the assumed solution <xref ref-type="disp-formula" rid="eqn2" hwp:id="xref-disp-formula-2-10" hwp:rel-id="disp-formula-2">Eq. (2)</xref>. Then
<disp-formula id="eqn20" hwp:id="disp-formula-20" hwp:rev-id="xref-disp-formula-20-1">
<alternatives hwp:id="alternatives-22"><graphic xlink:href="298836_eqn20.gif" position="float" orientation="portrait" hwp:id="graphic-27"/></alternatives>
</disp-formula>
With the initial condition
<disp-formula id="eqn21" hwp:id="disp-formula-21">
<alternatives hwp:id="alternatives-23"><graphic xlink:href="298836_eqn21.gif" position="float" orientation="portrait" hwp:id="graphic-28"/></alternatives>
</disp-formula>
the integration constant is determined as
<disp-formula id="eqn22" hwp:id="disp-formula-22">
<alternatives hwp:id="alternatives-24"><graphic xlink:href="298836_eqn22.gif" position="float" orientation="portrait" hwp:id="graphic-29"/></alternatives>
</disp-formula>
Insertion into <xref ref-type="disp-formula" rid="eqn20" hwp:id="xref-disp-formula-20-1" hwp:rel-id="disp-formula-20">Eq. (20)</xref> after some algebra yields
<disp-formula id="eqn23" hwp:id="disp-formula-23">
<alternatives hwp:id="alternatives-25"><graphic xlink:href="298836_eqn23.gif" position="float" orientation="portrait" hwp:id="graphic-30"/></alternatives>
</disp-formula>
which is what needed to be shown.</p><p hwp:id="p-64">For the tissue compartment the base case is calculated for <italic toggle="yes">T</italic><sub>0</sub>:
<disp-formula id="eqn24" hwp:id="disp-formula-24">
<alternatives hwp:id="alternatives-26"><graphic xlink:href="298836_eqn24.gif" position="float" orientation="portrait" hwp:id="graphic-31"/></alternatives>
</disp-formula>
where the explicit solution for <italic toggle="yes">S</italic><sub>0</sub> was inserted. This equation is solved with <xref ref-type="disp-formula" rid="eqn18" hwp:id="xref-disp-formula-18-1" hwp:rel-id="disp-formula-18">Eq. (18)</xref> and the initial condition <italic toggle="yes">T</italic><sub>0</sub>(<italic toggle="yes">t</italic><sub>0</sub>) = <italic toggle="yes">τ</italic><sub>0</sub> is used to yield
<disp-formula id="eqn25" hwp:id="disp-formula-25">
<alternatives hwp:id="alternatives-27"><graphic xlink:href="298836_eqn25.gif" position="float" orientation="portrait" hwp:id="graphic-32"/></alternatives>
</disp-formula>
This shows that the explicit solution of <italic toggle="yes">T</italic><sub>0</sub> is consistent with the general solution <xref ref-type="disp-formula" rid="eqn2" hwp:id="xref-disp-formula-2-11" hwp:rel-id="disp-formula-2">Eq. (2)</xref>. Now the solution <xref ref-type="disp-formula" rid="eqn2" hwp:id="xref-disp-formula-2-12" hwp:rel-id="disp-formula-2">Eq. (2)</xref> is assumed valid for <italic toggle="yes">T</italic><sub><italic toggle="yes">i</italic></sub>. Then
<disp-formula id="eqn26" hwp:id="disp-formula-26">
<alternatives hwp:id="alternatives-28"><graphic xlink:href="298836_eqn26.gif" position="float" orientation="portrait" hwp:id="graphic-33"/></alternatives>
</disp-formula>
where <italic toggle="yes">S</italic><sub><italic toggle="yes">i</italic></sub><sub>+1</sub> is known from the already proven solution <xref ref-type="disp-formula" rid="eqn2" hwp:id="xref-disp-formula-2-13" hwp:rel-id="disp-formula-2">Eq. (2)</xref> and <italic toggle="yes">T</italic><sub><italic toggle="yes">i</italic></sub> can be inserted from the assumed solution. Again <xref ref-type="disp-formula" rid="eqn18" hwp:id="xref-disp-formula-18-2" hwp:rel-id="disp-formula-18">Eq. (18)</xref> can be applied with
<disp-formula id="eqn27" hwp:id="disp-formula-27">
<alternatives hwp:id="alternatives-29"><graphic xlink:href="298836_eqn27.gif" position="float" orientation="portrait" hwp:id="graphic-34"/></alternatives>
</disp-formula>
Together with
<disp-formula id="eqn28" hwp:id="disp-formula-28">
<alternatives hwp:id="alternatives-30"><graphic xlink:href="298836_eqn28.gif" position="float" orientation="portrait" hwp:id="graphic-35"/></alternatives>
</disp-formula>
and some algebra, one finds
<disp-formula id="eqn29" hwp:id="disp-formula-29" hwp:rev-id="xref-disp-formula-29-1">
<alternatives hwp:id="alternatives-31"><graphic xlink:href="298836_eqn29.gif" position="float" orientation="portrait" hwp:id="graphic-36"/></alternatives>
</disp-formula>
With the initial condition <italic toggle="yes">T</italic><sub><italic toggle="yes">i</italic></sub><sub>+1</sub>(<italic toggle="yes">t</italic><sub>0</sub>) = <italic toggle="yes">τ</italic><sub><italic toggle="yes">i</italic></sub><sub>+1</sub> the integration constant is determined as
<disp-formula id="eqn30" hwp:id="disp-formula-30">
<alternatives hwp:id="alternatives-32"><graphic xlink:href="298836_eqn30.gif" position="float" orientation="portrait" hwp:id="graphic-37"/></alternatives>
</disp-formula>
Insertion in <xref ref-type="disp-formula" rid="eqn29" hwp:id="xref-disp-formula-29-1" hwp:rel-id="disp-formula-29">Eq. (29)</xref>, resorting, and renumbering of the sum indices yields:
<disp-formula id="eqn31" hwp:id="disp-formula-31">
<alternatives hwp:id="alternatives-33"><graphic xlink:href="298836_eqn31.gif" position="float" orientation="portrait" hwp:id="graphic-38"/></alternatives>
</disp-formula>
which proves the solution <xref ref-type="disp-formula" rid="eqn2" hwp:id="xref-disp-formula-2-14" hwp:rel-id="disp-formula-2">Eq. (2)</xref> for all <italic toggle="yes">i</italic>.</p></sec></sec><sec sec-type="supplementary-material" hwp:id="sec-24"><title hwp:id="title-34">Supplementary figures</title><fig id="figS1" position="float" fig-type="figure" orientation="portrait" hwp:id="F7" hwp:rev-id="xref-fig-7-1"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;298836v1/FIGS1</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F7</object-id><object-id pub-id-type="publisher-id">figS1</object-id><label>Supplementary Figure 1:</label><caption hwp:id="caption-8"><title hwp:id="title-35">Constant renewal with intermediate turnover rates.</title><p hwp:id="p-65">Same analysis and representation as in <xref rid="fig3" ref-type="fig" hwp:id="xref-fig-3-13" hwp:rel-id="F3">Figure 3</xref> but for organs with intermediate turnover (see <xref rid="tbl1" ref-type="table" hwp:id="xref-table-wrap-1-12" hwp:rel-id="T1">Table 1</xref>).</p></caption><graphic xlink:href="298836_figS1" position="float" orientation="portrait" hwp:id="graphic-39"/></fig><fig id="figS2" position="float" fig-type="figure" orientation="portrait" hwp:id="F8" hwp:rev-id="xref-fig-8-1"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;298836v1/FIGS2</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F8</object-id><object-id pub-id-type="publisher-id">figS2</object-id><label>Supplementary Figure 2:</label><caption hwp:id="caption-9"><title hwp:id="title-36">Age-dependent renewal rate for higher turnover organs.</title><p hwp:id="p-66">Same analysis (i.e. inducing absolute renewal rates by the treatment) and representation as in <xref rid="fig5" ref-type="fig" hwp:id="xref-fig-5-6" hwp:rel-id="F5">Figure 5A,B</xref> but for organs with intermediate (<bold>A,B</bold>) or high (<bold>C,D</bold>) turnover (see <xref rid="tbl1" ref-type="table" hwp:id="xref-table-wrap-1-13" hwp:rel-id="T1">Table 1</xref>).</p></caption><graphic xlink:href="298836_figS2" position="float" orientation="portrait" hwp:id="graphic-40"/></fig><fig id="figS3" position="float" fig-type="figure" orientation="portrait" hwp:id="F9" hwp:rev-id="xref-fig-9-1 xref-fig-9-2"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;298836v1/FIGS3</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F9</object-id><object-id pub-id-type="publisher-id">figS3</object-id><label>Supplementary Figure 3:</label><caption hwp:id="caption-10"><title hwp:id="title-37">Impact of higher turnover rates.</title><p hwp:id="p-67">Same analysis (i.e. inducing relative improvements of the renewal rate by the treatment) and representation as in <xref rid="fig5" ref-type="fig" hwp:id="xref-fig-5-7" hwp:rel-id="F5">Figure 5C,D</xref> but for organs with intermediate (<bold>A,B</bold>) or high (<bold>C,D</bold>) turnover (see <xref rid="tbl1" ref-type="table" hwp:id="xref-table-wrap-1-14" hwp:rel-id="T1">Table 1</xref>). The hierarchy, that organ failure happens the later the older the treated individual is restored (<bold>A,C</bold>). Cancer risk analysis (<bold>B,D</bold>) is consistent with the case of constant replication rate <italic toggle="yes">p</italic> (compare <xref rid="fig3" ref-type="fig" hwp:id="xref-fig-3-14" hwp:rel-id="F3">Figure 3</xref>).</p></caption><graphic xlink:href="298836_figS3" position="float" orientation="portrait" hwp:id="graphic-41"/></fig><fig id="figS4" position="float" fig-type="figure" orientation="portrait" hwp:id="F10" hwp:rev-id="xref-fig-10-1"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;298836v1/FIGS4</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F10</object-id><object-id pub-id-type="publisher-id">figS4</object-id><label>Supplementary Figure 4:</label><caption hwp:id="caption-11"><title hwp:id="title-38">The organ turnover rate associated with age-independent treatment success.</title><p hwp:id="p-68">Same analysis and representation as in <xref rid="fig5" ref-type="fig" hwp:id="xref-fig-5-8" hwp:rel-id="F5">Figure 5</xref> with the critical death rate <italic toggle="yes">δ</italic> = 0.023 per year, at which the age of first treatment becomes irrelevant for the retardation of organ failure. Relative impact of treatment on stem cell replication.</p></caption><graphic xlink:href="298836_figS4" position="float" orientation="portrait" hwp:id="graphic-42"/></fig><fig id="figS5" position="float" fig-type="figure" orientation="portrait" hwp:id="F11" hwp:rev-id="xref-fig-11-1 xref-fig-11-2"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;298836v1/FIGS5</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F11</object-id><object-id pub-id-type="publisher-id">figS5</object-id><label>Supplementary Figure 5:</label><caption hwp:id="caption-12"><title hwp:id="title-39">Rejuvenation treatment in mouse and human.</title><p hwp:id="p-69">Same experiment as in <xref rid="fig6" ref-type="fig" hwp:id="xref-fig-6-5" hwp:rel-id="F6">Figure 6</xref> but for relative induced stem cell replication rates (horizontal axes). (<bold>A</bold>) Mouse, age-dependent renewal, treated 5 weeks. (<bold>B</bold>) Human, age-dependent renewal, high turnover organ, treated 5 weeks. (<bold>C</bold>) Human, age-independent renewal, high turnover organ, treated 5 weeks. (<bold>D</bold>) Human, age-dependent renewal, low turnover organ, treated 2 years.</p></caption><graphic xlink:href="298836_figS5" position="float" orientation="portrait" hwp:id="graphic-43"/></fig><fig id="figS6" position="float" fig-type="figure" orientation="portrait" hwp:id="F12" hwp:rev-id="xref-fig-12-1"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;298836v1/FIGS6</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F12</object-id><object-id pub-id-type="publisher-id">figS6</object-id><label>Supplementary Figure 6:</label><caption hwp:id="caption-13"><title hwp:id="title-40">Constant renewal rate with cancer induced at <italic toggle="yes">c</italic> = 20 mutations.</title><p hwp:id="p-70">Same analysis and representation as in <xref rid="fig3" ref-type="fig" hwp:id="xref-fig-3-15" hwp:rel-id="F3">Figure 3</xref> with low (<bold>A,B</bold>) and high (<bold>C,D</bold>) turnover rates (see <xref rid="tbl1" ref-type="table" hwp:id="xref-table-wrap-1-15" hwp:rel-id="T1">Table 1</xref>).</p></caption><graphic xlink:href="298836_figS6" position="float" orientation="portrait" hwp:id="graphic-44"/></fig><fig id="figS7" position="float" fig-type="figure" orientation="portrait" hwp:id="F13" hwp:rev-id="xref-fig-13-1"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;298836v1/FIGS7</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F13</object-id><object-id pub-id-type="publisher-id">figS7</object-id><label>Supplementary Figure 7:</label><caption hwp:id="caption-14"><title hwp:id="title-41">Steep or flat age-dependence of the renewal rate.</title><p hwp:id="p-71">Same analysis and representation as in <xref rid="fig5" ref-type="fig" hwp:id="xref-fig-5-9" hwp:rel-id="F5">Figure 5C,D</xref> with flat (<italic toggle="yes">n</italic> = 1.5, <bold>A,B</bold>) and steep (<italic toggle="yes">n</italic> = 3, <bold>C,D</bold>) age-dependence in <xref ref-type="disp-formula" rid="eqn15" hwp:id="xref-disp-formula-15-5" hwp:rel-id="disp-formula-15">Eq. (15)</xref>. Parameters of low turnover rates (see <xref rid="tbl1" ref-type="table" hwp:id="xref-table-wrap-1-16" hwp:rel-id="T1">Table 1</xref>).</p></caption><graphic xlink:href="298836_figS7" position="float" orientation="portrait" hwp:id="graphic-45"/></fig><fig id="figS8" position="float" fig-type="figure" orientation="portrait" hwp:id="F14" hwp:rev-id="xref-fig-14-1"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;298836v1/FIGS8</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F14</object-id><object-id pub-id-type="publisher-id">figS8</object-id><label>Supplementary Figure 8:</label><caption hwp:id="caption-15"><title hwp:id="title-42">Increased total cell numbers.</title><p hwp:id="p-72">Same analysis and representation as in <xref rid="fig5" ref-type="fig" hwp:id="xref-fig-5-10" hwp:rel-id="F5">Figure 5C,D</xref> with 1000 times more cells (<bold>A,B</bold>) and 10 times more stem cells (<bold>C,D</bold>). There is no impact by construction. Using age-dependent renewal rate and relative improvement in 10 years treatments. Parameters of low turnover rates (see <xref rid="tbl1" ref-type="table" hwp:id="xref-table-wrap-1-17" hwp:rel-id="T1">Table 1</xref>).</p></caption><graphic xlink:href="298836_figS8" position="float" orientation="portrait" hwp:id="graphic-46"/></fig></sec></back></article>
